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EXECUTIVE SUMMARY  
In 2017, Indiana University, in cooperation with Indiana Governor Eric Holcomb and community partners, launched the Grand Challenge: 
Responding to the Addictions Crisis initiative, a university-wide effort to advance interdisciplinary research and interventions in response to the 
substance abuse crisis affecting Indiana and the nation. The “Legal and Policy Best Practices in Response to the Substance Abuse Crisis” project is 
one of sixteen funded under Phase 1 of the Grand Challenge. This preliminary report outlines the initial findings of the project.  
Specifically, this report describes the results of a qualitative study that surveyed individuals with expertise related to the substance abuse crisis 
in Indiana for their thoughts and perspectives on effective law and policy interventions. Based on this information and additional original 
research, this report also analyzes select law and policy areas identified as promising interventions to combat the substance abuse crisis in 
Indiana. The report identifies general or medium-term law and policy issues, a list of specific findings that may be appropriate for more 
immediate action, and a suggestion of topics requiring further research across eight categories: 
Findings Government Level 
Federal State Local 
Harm Reduction, Preliminary Report p. 21 
Repeal requirement that bystander immunity be linked to administration of overdose 
intervention drugs 
 *  
Extend overdose immunity to individual needing medical assistance  *  
Extend overdose immunity to include more violations  *  
Extend overdose immunity to individual possessing a syringe from a syringe exchange program  *  
Implement safe station programs  * * 
Healthcare Interventions, Preliminary Report p. 27 
Provide resources to better integrate syringe exchange programs with other treatment and 
services 
* * * 
Provide evidence-based treatment to Indiana's jail population   * * 
Provide wrap-around services to those in recovery or during re-entry * * * 
Evaluate needs of addictions and healthcare workforce * * * 
Look beyond existing intervention models and explore potential for county or regional rapid 
stabilization models of care 
 * * 
Reduce administrative barriers to receiving Medicaid services * *  
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Care Coordination and Wrap-Around Services, Preliminary Report p. 34 
Allow prisoner re-entry, safe and supportive housing, vocational services, and other wrap-around 
services to qualify as Medicaid reimbursable products 
* *  
Evaluate provision of wrap-around services for 6-12 months for SUD individuals who successfully 
complete a treatment program 
 *  
Reexamine premium requirements, administrative requirements, and penalties such as lock-outs 
and negative HIP tiering for persons with SUD to reduce care coordination costs 
 *  
Consider making additional waiver requests from CMS to provide care coordination and wrap-
around services that lead to Medicaid savings 
* *  
Fund demonstration projects to examine novel approaches to providing coordinated care for 
SUD population 
* *  
Examine feasibility of delaying introduction of HIP eligibility and maintenance of benefits reforms 
as they apply to SUD population until crisis shows signs of abatement 
 *  
Reinstate Medicaid services for incarcerated individuals 30 days prior to their release  *  
Drug Take Back Programs, Preliminary Report p. 38 
Develop, implement, and support more flexible local take back programs  * * 
Patient Privacy Protections, Preliminary Report p. 40 
Clarify limited role of "psychotherapy notes" provision, and instruct providers that it does not 
justify a refusal to share substance use or mental health records 
*   
Clarify how "emergency" carve-outs in the two regulations operate and provide detailed 
instructions on how to navigate them 
*   
Identify and promote specific, lawful data-sharing frameworks and technical workflows that 
minimize barriers cause by the differential protections 
*   
OCR and SAMHSA should issue explicit joint enforcement guidance that minimizes clinicians' 
concerns over legal implications of dealing with these privacy laws 
*   
Courts, Preliminary Report p. 44 
Assess the knowledge, attitudes, beliefs, and behaviors of those working in the court systems 
related to MAT and SUD 
 *  
Evaluate the variation in entry requirements for the state's drug courts  *  
Update assessment of the decade-old, limited outcomes evaluation of Indiana's state drug courts  *  
Explore effectiveness of using the Indiana 2-1-1 system to aid in identify area inpatient and 
community-based treatment options for those with community-based sentences and/or 
probation 
 *  
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Identify and evaluate court policies addressing the interaction of judges with pharmaceutical and 
medical device representatives 
 *  
Proceeds from Opioids Litigation, Preliminary Report p. 49 
Support inclusion of language in any opioids settlement that directs the majority of settlement 
funds be spent on treatment and health care related to opioid addictions 
 * * 
Pass legislation that commits the state to responsible and relevant "best practices" expenditures 
that prioritize substance use harm reduction, treatment, and education 
 *  
Stigma, Preliminary Report p. 53 
Encourage education campaigns directed toward providers, as well as the public, on MAT and 
naloxone 
* * * 
Assess impact on knowledge, attitudes and beliefs of Indiana Supreme Court educational 
program in July 2018 for those who work in court system 
 *  
Policymaking bodies should, whenever possible, include the voices of those directly impacted by 
SUD, including family members and current or former SUD service recipients 
* * * 
Legal and Policy Best Practices in Response to the Substance Abuse Crisis 
7  |  April 26, 2018 
 
INTRODUCTION  
The Grand Challenge 
In 2017, Indiana University (IU), in cooperation with Indiana Governor Eric Holcomb and community 
partners, launched the Grand Challenge: Responding to the Addictions Crisis initiative, a university-wide 
effort to advance interdisciplinary research and interventions in response to the substance abuse crisis 
affecting Indiana and the nation.1 
 
The three overarching goals of the Addictions Crisis Grand Challenges initiative are to: 
● Reduce the incidence of substance use disorders (SUD); 
● Decrease opioid deaths; and,  
● Decrease the number of babies born with neonatal abstinence syndrome (NAS). 
The Grand Challenge seeks to leverage the strengths of IU in the following domains: (1) data sciences 
and analytics; (2) education, training, and certification; (3) policy analysis, economics, and law; (4) basic, 
applied, and translational research; and (5) community and workforce development. 
This Project 
The “Legal and Policy Best Practices in Response to the Substance Abuse Crisis” project is one of sixteen 
funded under Phase 1 of the Grand Challenge: Responding to the Addictions Crisis initiative and focuses 
on law and policy. The project team consists of researchers at the IU Robert H. McKinney School of Law 
(McKinney Law) and IU Richard M. Fairbanks School of Public Health (FSPH) at Indiana University-Purdue 
University Indianapolis (IUPUI; see Appendix A: Research Team Biographies). Researchers investigated 
and analyzed the content and implementation of local, state, and federal laws and policies related to the 
substance abuse crisis and conducted interviews with key stakeholders with expertise related to these 
law and policy concerns. Informed by the evidence collected, the project’s primary goals were to identify 
and assess opportunities to improve the effectiveness of Indiana law and policy implicated in the State’s 
response to the substance abuse crisis. 
As noted above, the causes of the current crisis are multifactorial. Research has identified effective 
policies and programs, implemented at an array of intervention points, that may reduce substance 
                                                          
1 Grand Challenges: Addictions, IND. UNIV., https://grandchallenges.iu.edu/addiction/index.html (last visited Mar. 25, 2018).  
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abuse and/or the adverse effects of substance abuse on health and society. However, how lawmakers, 
and those who interpret and implement laws, define and identify problems, set priorities, and invest in 
legal and policy responses, often deviate from the research evidence. Their actions tend to be mediated 
by divergent political, professional, and personal philosophies and language. 
The report identifies general or medium-term law and policy issues, a list of specific findings that may be 
appropriate for more immediate action, and a suggestion of topics requiring further research.  
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BACKGROUND 
A study by the Center for Health Policy (CHP), a research hub of the FSPH Department of Health Policy 
and Management, found nearly one in twelve Hoosiers—almost a half million people—meet the criteria 
for having an SUD.2 Approximately four thousand Hoosiers have died from opioids in the last decade,3 
and the drug-induced mortality rate in Indiana quadrupled between 2000 and 2014.4 In 2015, the 
Indiana State Department of Health (ISDH) reported the overwhelming number of poisoning deaths in 
Indiana were caused by overdoses and far exceeded vehicular traffic-related deaths.5 In addition to this 
preventable loss of life, the economic cost of drug overdose deaths to Indiana in 2014 was estimated at 
$1.4 billion.6  
 
The substance abuse crisis is a rapidly moving target. For example, recent literature based on emergency 
department data on overdoses, published by the Centers for Disease Control and Prevention (CDC), 
demonstrates a considerable worsening of the substance abuse crisis, including a sharp spike in the 
Midwest, particularly in Indiana.7 
Note: The phrases “opioid abuse” and “opioid abuse crisis” are part of the larger substance use disorder 
(SUD) and substance abuse crisis research covered in this report. While interchanged periodically, all 
phrases touch on the same project focus. Additionally, interviewees spoke on opioid abuse when 
specifically discussing the substance abuse crisis in both Indiana and the United States. 
                                                          
2 HAROLD KOOREMAN & MARION GREENE, TREATMENT & RECOVERY FOR SUBSTANCE USE DISORDERS IN INDIANA, IND. UNIV. CTR. FOR HEALTH POLICY 
16-H80 (Lyndy Kouns ed., 2016), available at https://fsph.iupui.edu/doc/researchcenters/Treatment%20and%20Recovery%202 
016.pdf.  
3 Bob Segall, So Many Bodies: Indiana Coroners Trying to Keep Up with Opioid Epidemic, WTHR (Nov. 15, 2017, 7:14PM), 
https://www.wthr.com/article/so-many-bodies-indiana-coroners-trying-to-keep-up-with-opioid-epidemic.  
4HAROLD KOOREMAN & MARION GREENE, TREATMENT & RECOVERY FOR SUBSTANCE USE DISORDERS IN INDIANA, IND. UNIV. CTR. FOR HEALTH POLICY 
16-H80, 4 (Lyndy Kouns ed., 2016), available at https://fsph.iupui.edu/doc/researchcenters/Treatment%20and%20Recovery%2 
02016.pdf.  
5 DIV. OF TRAUMA AND INJURY PREVENTION, SPECIAL EMPHASIS REPORT: DRUG OVERDOSE DEATHS, 1999-2015, IND. STATE DEPT. OF HEALTH (2017) 
https://www.in.gov/isdh/files/2017_SER_Drug_Deaths_Indiana.pdf.  
6 JOAN DUWVE, ET AL., REPORT ON THE TOLL OF OPIOID USE IN INDIANA AND MARION COUNTY, RICHARD M. FAIRBANKS SCH. OF PUB. HEALTH (2016), 
available at https://www.inphilanthropy.org/sites/default/files/Richard%20M.%20Fairbanks%20Opioid%20Report%20Septemb 
er%202016.pdf.  
7 Alana M. Vivolo-Kantor et al., VItal Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses — United 
States, July 2016–September 2017, 67 MORB. MORTAL. WKLY. REP. 279 (2018), available at 
http://dx.doi.org/10.15585/mmwr.mm6709e1.  
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Not only are these numbers in flux, but the sources of the problem and so, to an extent, the possible 
solutions continue to evolve.8 Over-promotion, overprescribing, and diversion of prescription opioids 
were significant contributors to the current substance use crisis. However, as indicated in the chart 
below, the crisis increasingly revolves around the abuse of non-prescription opioids by non-medical 
users. Further, the substance abuse crisis goes beyond opioids, with the United States Drug Enforcement 
Administration (DEA) recently reporting a significant spike in the availability and use of cocaine, and 
methamphetamine traffic from Mexico on the rise nationwide.9 
Indeed, this preliminary report’s research and detailed views of interviewees are consistent with one 
evolving view of the substance abuse crisis; there exists not just one crisis, but two: 
The first is the prescription-drug epidemic—highly visible to the public, and more likely 
to occur among older adults in rural, white communities who misuse prescription 
painkillers. The second, more recently emerging epidemic, is among younger adults who 
are victims of illegally produced opioids such as fentanyl. Urban communities of color 
have recently witnessed a surge in deaths resulting from these illegally produced 
opioids.10 
                                                          
8 Overdose Death Rates, NATIONAL INSTITUTE ON DRUG ABUSE, https://www.drugabuse.gov/related-topics/trends-
statistics/overdose-death-rates (last updated Sept. 2017).  
9 DRUG ENFORCEMENT ADMINISTRATION, 2017 NATIONAL DRUG THREAT ASSESSMENT, DEA-DCT-DIR-040-17 (2017), https://www.dea.gov/ 
docs/DIR-040-172017-NDTA.pdf. See, also, Peter Phalen et. al., Fentanyl related overdose in Indianapolis: Estimating trends 
using multilevel Bayesian models, (ADDICT. BEHAV. Forthcoming 2018), available at https://www.sciencedirect.com/science/ 
article/abs/pii/S0306460318301217; Christine Vestal, A New Meth Surge Gathers Momentum, THE PEW CHARITABLE TRUSTS (May 
18, 2017), http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/05/18/a-new-meth-surge-gathers-
momentum.  
10 Shanoor Seervai, Arnav. Shah, & Eric C. Schneider, The U.S. Has Two Opioid Epidemics: The Federal Response Should Consider 
Both, TO THE POINT (Mar. 22, 2018), http://www.commonwealthfund.org/publications/blog/2018/mar/federal-response-to-
opioids. 
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As the research team moves forward and considers legal and policy changes to combat these crises, it is 
important to account for whether suggested changes address both crises, or only one. 
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METHODOLOGY 
This section describes the methodology used to develop this preliminary report, including the 
combination of prior research, interviewee data, and original research. Project scoping and design also 
are addressed. 
Prior Expert Reports 
In narrowing down topics for detailed study, the research team drew upon and analyzed prior national 
reports on the opioid and overarching substance abuse crises. In particular, the research team assessed 
and compared findings from The 2016 Surgeon General’s Report,11 the 2017 President’s Commission on 
Combating Drug Addiction and the Opioid Crisis,12 and the 2018 National Governors Association 
Recommendations for Federal Action to End the Nation’s Opioid Crisis.13 
This project’s research also benefited immeasurably from studying the report from Governor Holcomb 
and Executive Director for Drug Prevention, Treatment, and Enforcement Jim McClelland, A Strategic 
Approach to Addressing Substance Abuse in Indiana14 and its accompanying Action Plan,15 and the 
earlier work of the Indiana Prescription Drug Abuse Prevention Task Force.16 
Expert Interviews 
The team conducted qualitative research by holding semi-structured interviews with an array of subject 
matter experts on laws and policies implicated in the substance abuse crisis response. The goal of these 
interviews was to 1) enhance the insights found during the independent research phase and 2) identify 
near-term, medium-term, and long-term opportunities for—and obstacles to—law and policy reform 
that would better align current response efforts with evidence-based and evidence-informed best 
practices.  
IU Institutional Review Board Approval 
Prior to beginning the expert interview process, the research team submitted an exemption application 
for the qualitative study with the IU Institutional Review Board (IRB), including the interview procedures, 
                                                          
11 Early Intervention, Treatment, and Management of Substance use Disorders, in Facing Addiction in America: The Surgeon 
General’s Report on Alcohol, Drugs, and Health, 4-1, 4-10 to 11 (2016), available at 
https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf. 
12 The President’s Commission on Combating Drug Addiction And The Opioid Crisis (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUES.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/.  
13 Governors' Recommendations for Federal Action to End the Nation’s Opioid Crisis, NATIONAL GOVERNORS ASSOCIATION, 5 (Jan. 18, 
2018), https://www.nga.org/files/live/sites/NGA/files/pdf/2018/OGR/Governors%27%20Recommendations%20for%20Federal 
%20Action%20to%20End%20the%20Nation%27s%20Opioid%20Crisis_0118.pdf.  
14 A Strategic Approach to Addressing Substance Abuse in Indiana (2017), IND. GOVERNOR’S OFFICE, http://www.in.gov/gov/files/A 
%20Strategic%20Approach%20to%20Addressing%20Substance%20Abuse%20in%20Indiana.pdf (last visited Mar. 29, 2018).  
15 Indiana Drug Prevention, Treatment and Enforcement Preliminary Action Steps, IND. GOVERNOR’S OFFICE (May 18, 2017), 
http://www.in.gov/gov/files/DPTE%20Preliminary%20Action%20Steps.pdf.  
16 INDIANA PRESCRIPTION DRUG ABUSE PREVENTION TASK FORCE, TAKING ACTION: THE FOUR YEAR REPORT 2012-2016, available at 
https://www.in.gov/bitterpill/files/FINAL%20Four%20Years%20In%20Action%20Report%20%20OAG%20Coverchange%20final.
pdf.  
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study information sheet, and sample interview questions. The exemption application was approved (IRB 
Study #1712454963, Protocol Exempt, Dec. 15, 2017).  
Interviewee Identification  
Interviewees were identified using a variety of channels. The research team first connected with their 
existing network of researchers, practitioners, and policymakers with expertise in the substance abuse 
crisis. These individuals were either invited to be interviewed or were asked to identify potential 
interviewees. Additionally, as part of some formal interviews, interviewees provided, or were asked to 
provide, additional recommendations.  
The research team selected their interviewees following substantial discussion of the individuals’ 
substantive areas of expertise (e.g., public health, criminal justice, healthcare) and their role in 
responding to the substance abuse crisis (e.g., state government official, researcher, insurer). The 
interviewee selection process aimed to secure breadth in the roles and expertise of these individuals. 
The initial project goal was to conduct interviews with at least 12 experts. Ultimately, the research team 
conducted 20 semi-structured interviews. Some interviews involved multiple persons. Not included in 
the data below are the multiple informal discussions held with leaders of the judiciary, state 
government officials, and other researchers, which served as background information for the research 
team. 
Interviewee Areas of Expertise and Role in Response 
Interviews were conducted with 20 key experts. The interviewees have been categorized into the 
following domains of substantive expertise (Figure 1), with some experts qualifying in multiple 
categories:  
1. Criminal Justice 
2. Healthcare 
3. Health Law 
4. Public Health 
5. Social Services 
6. Health Policy  
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The role or roles each interviewee plays in the substance abuse crisis response varied across nine 
categories. Some experts covered more than one category, as shown in Figure 2:  
1. Community Agency 
2. Healthcare Provider 
3. Health Insurer 
4. Judiciary 
5. Law Enforcement 
6. Local Government 
7. Researcher 
8. State Government 
 
In the interview selection process, two limitations were noted. First, the research team had a relatively 
short time frame to conduct interviews (mid-January to mid-March 2018). It therefore was imperative 
that the team be strategic in selecting individuals. Thus, comprehensiveness in the expertise areas and 
roles of interviewees could not be achieved. Second, although the goal was to pursue broad 
representation in role and expertise of interviewees, the team recognized this process is subject to 
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selection bias and cannot represent all individuals with expertise and experience with law and policy 
barriers relating to the substance abuse crisis.  
Interview Process 
Once identified, interviewees were sent a formal invitation to participate in the study. The invitation 
included a study information sheet (Appendix B: Disclosure to Interviewees), outlining the purpose and 
procedures of the study. Interviews were conducted in person, via conference call, or via video 
conferencing. The interviews lasted between 30-75 minutes, with most interviews lasting between 45-
60 minutes.  
Interviews were semi-structured. The research team directed a common set of open-ended questions to 
all interviewees and customized additional questions for each interviewee based upon their particular 
areas of expertise. See Appendix C: Sample Questions for sample interview questions.  
Original Research 
Using information collected from academic scholarship, prior expert reports, and key interviews, the 
team identified areas meriting additional research. Researchers utilized the Indiana General Assembly 
web site (iga.in.gov) and subscription-only legal research databases (WestlawNext and LexisNexis), to 
collect relevant statutes, regulations, and case law, as well as PubMed and search engines to collect 
scientific literature and information from state and federal agencies. The goal of this research was to 
identify and analyze evidence-based and evidence-informed substance use crisis-related law and policy 
interventions.  
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Scoping 
From the inception of this project, the team was fully cognizant that not only was the research following 
in the footsteps of others who have examined these issues at both the federal and state level, but also 
that currently in Indiana, this team is not the only group working on these issues. The team is familiar 
with and continually impressed by the positive steps taken by Governor Holcomb’s Commission to 
Combat Drug Abuse, members of the Indiana legislature, the leadership of Indiana's court system, and 
the ongoing research of the Pew Charitable Trust, as well as innumerable initiatives led by state and 
local agencies, law enforcement, healthcare providers, charitable organizations, communities, 
researchers, and many committed individuals. 
Those agencies or individuals that work or research issues related to substance abuse long ago knew 
that they face a “wicked problem.” Using this frame, an addictions medical doctor recently described 
the opioid crisis as follows: 
Those who advocate for reducing opioid prescribing fail to see the Ohio experience 
where opioid use simply went underground or shifted to illicit drugs. Those who 
advocate for no adjustment to opioid prescribing fail to see the correlation between 
prescribing and overdoses observed in many communities. Those who argue that this is 
purely a problem of social determinants of health fail to see the overdose and addiction 
rates in affluent communities. Those who argue that medication assisted treatment 
(MAT) will solve the problem fail to see that most patients who are prescribed MAT do 
not continue it, and in fact relapse to opioids . . . . Those who push an access-to-care 
argument fail to see that access is just the first step − we need appropriate utilization of 
resources. Those who are going after the “opioid crisis” fail to see that over 50% of 
opioids in the US are prescribed to people with mental health conditions and unless we 
treat those underlying mental disorders, we cannot solve this problem.17 
The Strategic Approach to Addressing Substance Use in Indiana report noted how the effectiveness of 
society’s response to the multifaceted substance abuse crisis will be governed in large part by the 
implementation, application, and enforcement of local, state, and federal law. The complex nature of 
this challenge includes, but is not limited to, addressing laws and policies related to mental health and 
addiction, criminal justice, child welfare, healthcare access and delivery, public health, education, public 
safety, and community engagement and resilience. Furthermore, research shows this crisis represents a 
syndemic, with multiple diseases and social determinants combining to create a complex web of 
intertwining challenges.  
The stakeholders involved in the response have widely varying backgrounds and experiences, both 
professional (criminal justice, healthcare, public health, law, non-governmental organizations, 
education, elected and non-elected government work, social science research) and personal (individual, 
familial, and community-lived experiences responding to the epidemic). These varying perspectives 
affect the way the parties define, identify, and prioritize problems associated with the substance abuse 
syndemic, as well as how they identify and measure success. Additionally, policies and laws passed and 
                                                          
17 Jonathan C. Lee, The Opioid Crisis is A Wicked Problem, 27 Am. J. Addict 51, 51 (2017), available at https://onlinelibrary.wiley 
.com/doi/epdf/10.1111/ajad.12662. 
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implemented to address substance abuse crisis challenges may result in the emergence and/or 
identification of previously unforeseen or underappreciated new challenges. 
The substance abuse crisis is one of the most complex challenges affecting the health of Indiana 
residents of all ages. An effective response to the problem requires evidence based and evidence 
informed multidisciplinary collaborations. As experts in healthcare law and policy, public health law, 
health data, and ethics, the team recognizes the unique role of law and health in the epidemic. The 
structure, interpretation, and application of laws and policies can act as impediments to evidence-based 
approaches to the substance abuse crisis. Equally, well-crafted laws and policies may offer opportunities 
to positively resolve the epidemic. 
Even after the application of narrower frames, such as law, policy, or public health, the scope of the 
problem and potential solutions are almost immeasurable. As a result, the team decided to narrow the 
scope of the project’s inquiry, conscious of each individual’s skill sets (expertise in and prior research on 
the public health system, healthcare delivery, healthcare data, and legal epidemiology). Additionally, 
many recent national and state reports have identified the same “low-hanging fruit,” including 
amelioratory measures designed to remedy the genus of legal barriers or associated policies that are the 
subject of this study. These measures have become “table stakes” in state efforts to combat the 
substance abuse crisis. Indiana has taken notable steps, moving past issue identification to 
implementation with regard to several of these proposals, by:  
● Making naloxone broadly available and increasing the number of persons who can administer it, 
in large part thanks to Aaron’s Law;18 
● Improving data management through initiatives, such as those led by the Data Management 
Hub, with the shared goal of improving data sharing among agencies and producing actionable 
information designed to help public health and other authorities address new outbreaks or 
concentrated hot spots;19 
● Expanding Prescription Drug Monitoring Programs (PDMP) to provide better information to 
prescribers and pharmacists, increase prescriber obligations to consult a PDMP during care 
delivery, and improve integration of PDMP in provider workflows by, for example, integrating 
the data into electronic health records (EHRs). Indiana is moving on these issues with, for 
example, changes to its INSPECT program and EHR-integration provided by Appriss Health;20 
● Establishing supply-side approaches to reducing the number of opioids in circulation, such as by 
placing limits on the prescription of opioids (as Indiana has done21), increasing physician 
education, and changes in reimbursement policy; 
● Increasing policing and other law enforcement efforts to reduce the supply of illegal drugs. This 
research team fully accepts that a major issue in the substance abuse crisis, both nationally and 
in Indiana, is the supply of illegal or diverted drugs.22 Indeed, the team recognizes the increased 
                                                          
18 Programs and Initiatives, OVERDOSE LIFELINE, INC., https://www.overdose-lifeline.org/programs-and-initiatives.html (last visited 
Mar. 25, 2018).  
19 Management Performance Hub, Opioid Epidemic, STATE OF INDIANA, http://www.in.gov/mph/930.htm (last visited Mar. 29, 
2018). 
20 INDIANA PROFESSIONAL LICENSING AGENCY, INDIANA TO INTEGRATE PRESCRIPTION DRUG MONITORING PROGRAM STATEWIDE (2017), available at 
https://www.in.gov/pla/files/Statewide%20Integration%208.24.17.pdf.  
21 IND. CODE § 25-1-9.7-2 (2018). 
22 The President’s Commission on Combating Drug Addiction And The Opioid Crisis 58-65 (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018). 
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supply of non-prescription drugs has been a crucial accelerant in the crisis and, as noted above, 
more overdoses are now caused by illegal drugs than prescription drugs. These findings support 
the continual and growing imperative of interdiction and enforcement. Additionally, the criminal 
law issues related to the substance abuse crisis are themselves evolving. For example, one 
interviewee noted “a huge increase in theft, shoplifting, prostitution, home invasions, 
carjacking—all to pay for drugs.” Other interviewees from the judiciary and law enforcement 
confirmed these trends.  
○ Notwithstanding, in general, there are relatively few legal or policy barriers to 
interdiction or enforcement (though clearly there may be resource constraints). Rather, 
criminal law and criminal justice constructs tend to flow in the opposite direction, 
creating barriers to some of the interventions that are discussed later in this report. In 
particular, many interviewees were critical of increased attempts to further criminalize 
aspects of the crisis. As one interviewee said, “we’re not going to arrest our way out of 
this, yet we still criminalize.” One interviewee from Indiana law enforcement reiterated 
that “being an addict is not a crime;” another noted that the role of law enforcement 
officers had changed to harm reduction and, increasingly, to introducing those with SUD 
to treatment.  
○ However, while the team has sought to strike the right balance between appropriate 
criminal enforcement and harm reduction, it also is acutely aware that, in Indiana, 
stakeholder views, public perceptions, and public policy are still evolving. 
Several interviewees expressed strong opinions on Indiana’s adoption or implementation of some of 
these table stakes initiatives. These perspectives may be issues the research team returns to examine 
and assess later in this research project. 
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FINDINGS: OVERARCHING THEMES 
As prior reports were analyzed and interviews were performed, the team was impressed by the 
commitment of persons from all domains to make a positive difference in the substance abuse crisis. 
Clearly, there are disagreements as to the causes of the current crisis. However, there is far more 
agreement as to its enormity and many of the steps necessary to address it; in particular, approaching 
the current crisis through increasing the delivery of and access to harm reduction strategies, treatment 
options and education. 
Even interviewees who were critical of the work of those in other domains noted that, when they met 
these colleagues in the many multiple stakeholder meetings that have been organized across Indiana, 
they were always impressed by the shared dedication of those they met. In short, there are no bad 
actors here, but rather hard-working public and private stakeholders, many of whom are working in silos 
(or in budding collaborations across disciplines) while coping with inadequate resources. 
In addition to questions tailored to their domain-expertise, the team asked all interviewees some 
general and open-ended questions. For example, all interviewees were asked how the crisis presented 
to them and impacted their work. The team also asked how each interviewee would define “success” in 
combating the crisis. 
The answers to these open-ended, incidental comments volunteered by interviewees in the course of 
answering detailed questions—in addition to the team’s concurrent literature reviews—were the basis 
for the following general findings: 
 
1. Role of Healthcare System. In many respects, the substance abuse crisis is a function of 
deficiencies in the overall healthcare system, both nationally and in Indiana. These deficiencies 
frequently are highlighted by pandemics, syndemics, or natural disasters. For example, concerns 
about or problems with healthcare delivery were quite apparent in the aftermath of Hurricane 
Katrina and during the Ebola outbreak. Crises, of whatever nature, stress the healthcare system, 
illustrating and exacerbating its weaknesses. 
a. The United States spends more on its healthcare than any other country yet receives 
less both in terms of the percentage of the population receiving care and the quality of 
the care provided. 
b. The list of symptoms and causative factors is long and includes: access problems 
(particularly for the very poor and the poor), high and increasing costs (including 
insurance costs, prescription drug costs, and cost-shifting), substandard care 
coordination, a frequently incoherent healthcare delivery model involving multiple 
types of entities and financing or reimbursement models, and severe deficiencies in 
data management and sharing. In short, fixing crises, such as the substance abuse crisis, 
depends on far more complex reform of the healthcare system. 
c. Absent that reform, and in the meantime, responses largely will attempt to mitigate 
symptoms, rather than many of the underlying causes.  
 
2. Broader Addiction Problem. The opioid epidemic is an addiction crisis, but it is not the only one 
the nation or Indiana have faced or will face in the future. The opioid epidemic is somewhat 
distinctive because some of its causes (drug over-prescription and misleading promotion) can be 
identified and some actors demonized. Its death toll also appears disproportionately high given 
the number of persons with OUD. However, at root the opioid epidemic is part of an addiction 
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problem that stretches back over a century, with each “crisis” tending to recycle “supply-side 
and criminal-justice approaches” rather than “an expanded public health response.”23 Until we 
solve the broader addiction problem, we will be treating somewhat varying symptoms, not root 
causes. 
 
3. Describing the Problem. Interviewees were asked to describe how the current substance abuse 
crisis presented to them in their professional capacities. Responses from persons across multiple 
domains included words or phrases such as “overwhelming,” “extremely enormous,” “the worst 
public health crisis” experienced in a career, “epidemic,” “out of control,” and “impacting all 
walks of life.” Some interviewees volunteered additional analyses such as:  
a. Prior public health crises have seemed manageable—the substance abuse crisis has so 
many different aspects that the infrastructure is unable to cope;  
b. There is a need for substantial increases in coordination across domains and agencies 
and the ending of policy and implementation silos; 
c. Solutions are going to require cross-disciplinary systems and coordination.  
 
4. Impact of Crisis on Indiana. Indiana is not unique among states in the seriousness of its 
substance abuse crisis. It is not even unique among Midwestern states (e.g., accurate parallels 
are frequently drawn to the situation in Ohio). However, there are some contributing issues that 
make the crisis particularly acute for Indiana. 
a. Although Indiana is somewhat-average on per capita healthcare spending and average 
on per capita filling of prescriptions at retail pharmacies,24 the State is one of the 
unhealthier states, particularly with regard to health behaviors and health outcomes.25 
While improving, Indiana funding for public health remains in the bottom third of all 
states, and Indiana is rated in the bottom ten states for infant and adult mortality rates, 
obesity, and smoking.26 Indiana is not one of the poorest states, yet 32% of Hoosiers are 
poor (<200% FPL).27 Furthermore, Indiana ranks in the bottom third for education and 
forty-eighth in the country for quality of life.28 
b. The intergenerational impact of the substance abuse crisis is particularly hard felt in 
Indiana. The State has seen some of the nation’s largest increases in children being 
removed from their homes by child protective services due to family drug use. In 2016, 
more than 1 out of every 2 cases of children removed from their homes by the Indiana 
Department of Child Services was due to drug or alcohol use by a parent—a rate that 
rose more than 50 percent since 2013.29  
 
5. Decentralization of Local Government. Indiana has 92 counties and a considerably 
decentralized local government infrastructure, including local public health departments and 
coroners. Several interviewees commented that this decentralized model created impediments 
to effective public health interventions compared to statewide or regional interventions. There 
                                                          
23 Herzberg et al, Recurring Epidemics of Pharmaceutical Drug Abuse in America: Time for an All-Drug Strategy. 106 Am. J. Public 
Health 408, 409 (2016), available at http://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.2015.302982. 
24 State Health Facts, KAISER FAMILY FOUNDATION, https://www.kff.org/statedata/ (last visited Mar. 25, 2018). 
25 America’s Health Rankings Annual Report (2017) https://assets.americashealthrankings.org/app/uploads/ahrannual17 
_complete-121817.pdf.  
26 About Indiana, U.S. NEWS, https://www.usnews.com/news/best-states/indiana (last visited Mar. 25, 2018).  
27 KAISER FAMILY FOUNDATION, MEDICAID IN INDIANA, (2017), available at http://files.kff.org/attachment/fact-sheet-medicaid-state-IN. 
28 About Indiana, U.S. NEWS, https://www.usnews.com/news/best-states/indiana (last visited Mar. 25, 2018).  
29 , INDIANA YOUTH INSTITUTE, 2018 KIDS COUNT DATA BOOK 16 (2018), available at https://s3.amazonaws.com/iyi-website/data-
book/2018-Indiana-KIDS-COUNT-Data-Book.pdf?mtime=20180205073618.  
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is at least some intuitive support for this opinion from news stories about Indiana counties 
either refusing to institute syringe exchange programs30 or prematurely ending them.31 The 
termination of local syringe exchange programs is itself a product of an outlier characteristic in 
Indiana law, as most states with syringe exchanges do not subject their programs to as frequent 
reviews for reauthorization as Indiana.32  
 
6. Healthcare Interventions. As previously noted, the reasons why the substance abuse crisis is a 
wicked problem include the identification of multiple causes and the advocacy for multiple 
solutions, some of which are mutually inconsistent or exhibit ideological or political biases. 
Notwithstanding, our interviewees were almost unanimous in their assessment of the current 
situation: 
a. Interviewees displayed broad, pragmatic agreement; the substance abuse crisis in 
Indiana has evolved to the point that improvements in healthcare interventions are 
imperative. 
b. Multiple interviewees said improving outcomes in response to the substance abuse 
crisis requires seeing these issues principally as health concerns. As such, most 
interviewees concentrated on barriers to intervention and intervention priorities. First, 
as multiple interviewees stated, given the availability of naloxone, “no one should die.” 
Second, those persons presenting with SUD typically should receive evidence-based 
medication-assisted treatment (MAT). 
  
                                                          
30 Shari Rudavsky, Why Marion County Doesn’t Have A Needle Exchange, INDY STAR (Dec. 17, 2017), https://www.indystar.com/ 
story/news/2017/12/17/why-marion-county-doesnt-have-needle-exchange/949707001/.  
31 Leigh Hedger, 2nd Indiana County Ends Needle Exchange, INDY STAR (Oct. 23, 2017), https://www.indystar.com/story/news 
/2017/10/23/2nd-indiana-county-ends-needle-exchange-one-official-citing-moral-concerns/787740001/. 
32 United States Centers for Disease Control and Prevention, Laws Related to Syringe Exchange, 
https://www.cdc.gov/hepatitis/policy/SyringeExchange.htm (last visited Mar. 29, 2018). 
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FINDINGS: SPECIFIC LAW AND POLICY INTERVENTIONS 
The research team identified eight law and policy areas meriting more detailed analysis. These topics do 
not purport to be comprehensive in terms of a coordinated law and policy response to the substance 
abuse crisis. Rather, they represent the initial findings that the team has evaluated based on a variety of 
factors including: 1) the results from expert interviews, 2) actionable solutions (based on perceived 
political feasibility), and 3) resources available to study this issue, generated by other institutions or 
government agencies. 
1. HARM REDUCTION 
A. Background  
Harm reduction refers to public health interventions that seek to minimize illness and injuries associated 
with drug use, rather than seeking to reduce the incidence of drug use.33 Examples of harm reduction 
interventions include increased naloxone availability,34 increased access to sterile syringes via syringe 
exchange programs,35 and safe consumption sites.36 
For example, Indiana’s naloxone access law was passed in 2015.37 This law permits healthcare providers 
to prescribe an overdose intervention drug, i.e. naloxone, without having to examine the individual.38 
The law was expanded the following year; now the Indiana State Department of Health (ISDH) is 
required to issue a statewide standing order for naloxone.39 Under this standing order, any entity can 
dispense or prescribe naloxone in accordance with the statutory requirements. The entity must register 
with ISDH and provide education and training to recipients of the drug.40 Prescribers, dispensers, and 
others who lawfully administer naloxone are immune from civil liability.41 Naloxone is available at over 
500 locations throughout the state, including pharmacies, addiction treatment centers, non-profit 
organizations, health departments, schools, and correction facilities.42 Additionally, Indiana law permits 
                                                          
33 UNITED NATIONS OFFICE ON DRUGS AND CRIME, REDUCING THE HARM OF DRUG USE AND DEPENDENCE https://www.unodc.org/ddt-
training/treatment/VOLUME%20D/Topic%204/1.VolD_Topic4_Harm_Reduction.pdf, (last visited Mar. 25, 2018) (citing, 
Costigan G, Crofts N, & Reid G., The Manual for Reducing Drug Related Harm in Asia. Melbourne: Centre for Harm Reduction, 
MacFarlane Burnet Centre for Medical Research and Asian Harm Reduction Network (2003)). 
34 Daniel Kim, Kevin S. Irwin, & Kaveh Khoshnood, Expanded Access to Naloxone: Options for Critical Response to the Epidemic 
of Opioid Overdose Mortality, 99 AM. J. PUBLIC HEALTH 402, 405 (2009), available at http://ajph.aphapublications.org/doi/abs/ 
10.2105/AJPH.2008.136937. 
35 Don C. Des Jarlais et al., Doing Harm Reduction Better: Syringe Exchange in the United States, 104 ADDICTION 1141 (2009), 
available at https://onlinelibrary.wiley.com/doi/full/10.1111/j.1360-0443.2008.02465.x. 
36 Tim Rhodes et al., Public Injecting And The Need for ‘Safe Environment Interventions’ in The Reduction of Drug-Related Harm, 
101 ADDICTION 1384 (2006), available at https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1360-0443.2006.01556.x. 
37 Pub.L. No. 32-2015 (codified as amended at Ind. Code 16-42-27-2 (2018)). 
38 Pub.L. No. 32-2015 (codified as amended at Ind. Code 16-42-27-2 (2018)).  
39 IND. CODE 16-42-27-2(f) (2018); see also State Health Commissioner Renews Naloxone Standing Order, INDIANA STATE DEPARTMENT 
OF HEALTH (June 2017), http://www.in.gov/activecalendar/EventList.aspx?view=EventDetails&eventidn=265808&information_id 
=270184&type&syndicate=syndicate.  
40 IND. CODE 16-42-27-2(a), (e) (2018). 
41 IND. CODE 16-42-27-3 (2018).  
42 Indiana Health Commissioner Extends Naloxone Availability, WANE.COM (June 30, 2017, 3:47 PM), http://wane.com/2017/ 
06/30/indiana-health-commissioner-extends-naloxone-availibility/; Save A Life: Help Prevent Overdose Deaths, INDIANA STATE 
DEPT. OF HEALTH, https://optin.in.gov/ (last visited Mar. 25, 2018).  
Legal and Policy Best Practices in Response to the Substance Abuse Crisis 
23  |  April 26, 2018 
 
schools to stock naloxone.43 However, the Indy Star reported in 2017 that many schools are hesitant to 
stock the drug and instead rely on school officers or emergency services.44  
Indiana law also permits local governments to operate syringe exchange programs (SEPs)45 in the event 
of “an epidemic of hepatitis C or HIV” when “the primary mode of transmission of hepatitis C or HIV in 
the county is through intravenous drug use.”46 The law requires SEPs to register with the state health 
department, have a healthcare provider oversee the program, and provide participants with information 
about addiction treatment, among other requirements.47 Several localities are currently operating SEPs, 
including Monroe County and Allen County.48 
While Indiana law does not authorize safe consumption sites, several jurisdictions outside of Indiana 
have implemented this harm reduction strategy, the first of its kind in the United States.49 Safe 
consumption sites are locations in which persons with SUD can consume drugs in an environment 
monitored by healthcare providers. This strategy minimizes injury and promotes overdose prevention.50 
Some evidence suggests these sites reduce the number of overdoses and can link individuals to 
addiction treatment opportunities.51 
B. Findings  
As outlined above, Indiana has incorporated several evidence-based harm reductions strategies into 
state law. However, additional opportunities exist to further promote such strategies to address the 
addictions crisis in regard to overdose immunity laws, drug paraphernalia laws, and safe stations.  
                                                          
43 IND. CODE 20-34-4.5 (2018). 
44 Emma Kate Fittes, Indiana Schools Can Stock Naloxone, But Will They?, INDYSTAR (Nov. 8, 2017, 9:52 AM), 
https://www.indystar.com/story/news/local/2017/11/08/why-some-indiana-schooshould-indiana-schools-stock-overdose-
reversing-drug-naloxone-why-some-say-the/585595001/. 
45 IND. CODE 16-41-7.5-1 et seq. (2018). 
46 IND. CODE 16-41-7.5-5(1) (2018).  
47 IND. CODE 16-41-7.5-6 (2018).  
48 Syringe Exchange Program, Monroe County Indiana, www.co.monroe.in.us/tsd/Community/HealthDepartment/Syringe 
ExchangeProgram.aspx (last visited Mar. 25, 2018); Syringe Services Program, THE FORT WAYNE-ALLEN COUNTY DEPT. OF HEALTH, 
http://www.allencountyhealth.com/get-informed/ssp/ (last visited Mar. 25, 2018).  
49 Let Cities Open Safe Injection Sites, THE NEW YORK TIMES (Feb. 24, 2018), 
https://www.nytimes.com/2018/02/24/opinion/sunday/drugs-safe-injection-sites.html; Seattle Budget Includes Money for 
Safe-Injection Site, KIRO (Nov. 21, 2017, 9:40 AM), https://www.kiro7.com/news/local/seattle-budget-includes-money-for-safe-
injection/651500019; Heather Knight, SF Safe Injection Sites Expected to be First in Nation, Open Around July 1, SAN FRANCISCO 
CHRONICLE (Feb. 5, 2018, 8:26 AM), https://www.sfchronicle.com/news/article/SF-safe-injection-sites-expected-to-be-first-in-
12553616.php; https://www.nytimes.com/2018/02/20/opinion/philadelphia-opioid-overdose-
treatment.html?rref=collection%2Fcolumn%2Ffixes&action=click&contentCollection=opinion&region=stream&module=stream
_unit&version=latest&contentPlacement=1&pgtype=collection; See also, Leo Beletsky et al., The Law (and Politics) of Safe 
Injection Facilities in The United States, 98 Am. J. Public Health 231 (2008), available at http://ajph.aphapublications.org/doi 
/abs/10.2105/AJPH.2006.103747.  
50 Leo Beletsky et al., The Law (and Politics) of Safe Injection Facilities in The United States, 98 Am. J. Public Health 231 (2008), 
available at http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2006.103747.  
51 Brandon DL Marshall et al., Reduction in Overdose Mortality After The Opening of North America’s First Medically Supervised 
Safer Injecting Facility, 377 THE LANCET 1429 (2011), available at http://www.thelancet.com/journals/lancet/article/PIIS0140-
6736(10)62353-7/abstract; Jennifer Ng, Christy Sutherland, & Michael R. Kolber, Does Evidence Support Supervised Injection 
Sites?, 63 CAN FAM PHYSICIAN 866 (2017), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685449/; Leo Beletsky et 
al., The Law (and Politics) of Safe Injection Facilities in The United States, 98 Am. J. Public Health 231 (2008), available at 
http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2006.103747.  
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1. Overdose Immunity Laws 
For friends and family members of an individual experiencing an overdose situation, fear of criminal 
liability, for themselves and the individual overdosing, is the primary factor deterring them from seeking 
emergency services.52 Overdose Immunity Laws, also known as 911 Immunity Laws and Good Samaritan 
Laws, seek to reduce preventable overdose deaths by providing immunity from criminal prosecution to 
bystanders and, in some jurisdictions, to individuals experiencing an overdose situation, thus eliminating 
the primary reason for failing to seek emergency care.53  
Indiana’s overdose immunity law was enacted in 201654 and provides criminal immunity for drug 
possession and drug paraphernalia charges to individuals that seek emergency medical assistance to aid 
someone in an overdose situation.55 To be eligible for immunity, an individual must meet the following 
requirements:  
1. Legally obtained an overdose intervention drug;56  
2. Administered an overdose intervention drug;57 
3. Provided the full name of individual experiencing an overdose and any relevant information 
requested by law enforcement;58 
4. Remained at the scene with the individual overdosing until emergency services arrived;59 
5. Cooperated with emergency personnel and law enforcement;60  
6. Encountered law enforcement when seeking to assist an individual experience an overdose.61 
Uniquely, Indiana is the only state in the country that links immunity to the administration of overdose 
intervention drugs.62 However, bystanders and individuals experiencing an overdose can be afforded a 
mitigated sentence if they were convicted of a drug-related crime, which was facilitated due to 
requesting emergency services.63 Multiple interviewees recommended that overdose immunity 
                                                          
52 See, Preventing the Consequences of Opioid Overdose: Understanding 911 Good Samaritan Laws, SAMHSA’S CENTER FOR THE 
APPLICATION OF PREVENTION TECHNOLOGIES (November 8, 2017), available at https://iu.app.box.com/file/267744244520; Zach Myers, 
Police Urge People to Call 911 to Report Overdoses Despite Risk of Arrest, FOX 59 (May 15, 2017), 
http://fox59.com/2017/05/15/police-urge-911-calls-for-overdoses-despite-risk-of-arrest/; K. Tobin, et al., Calling Emergency 
Medical Services during Drug Overdose: An Examination of Individual, Social and Setting Correlates, 100 ADDICTION 397, 398 
(2005). 
53 SAMHSA’s CENTER FOR THE APPLICATION OF PREVENTION TECHNOLOGIES, PREVENTING THE CONSEQUENCES OF OPIOID OVERDOSE: UNDERSTANDING 
911 GOOD SAMARITAN LAWS (2017), available at https://www.samhsa.gov/capt/sites/default/files/resources/good-samaritan-law-
tool.pdf. 
54 2016 Ind. Legis. Serv. P.L. 6-2016 (S.E.A. 187).  
55 IND. CODE § 16-42-27-2(g), (h) (2018). 
56 IND. CODE § 16-42-27-2(g)(1), (2) (2018). 
57 IND. CODE § 16-42-27-2(g)(3) (2018). 
58 IND. CODE § 16-42-27-2(g)(4) (2018).  
59 IND. CODE § 16-42-27-2(g)(5) (2018). 
60 IND. CODE § 16-42-27-2(g)(5) (2018). 
61 IND. CODE § 16-42-27-2(g)(6) (2018). 
62 See, Drug Overdose Immunity and Good Samaritan Laws, NATIONAL CONFERENCE OF STATE LEGISLATURES (Jun. 5, 2017), 
http://www.ncsl.org/research/civil-and-criminal-justice/drug-overdose-immunity-good-samaritan-laws.aspx#Calling 911; see 
also, Legal Science, Good Samaritan Overdose Prevention Laws, PRESCRIPTION DRUG ABUSE POLICY SYSTEM, 
http://pdaps.org/datasets/good-samaritan-overdose-laws-1501695153 (last updated Dec. 1, 2016). 
63 IND. CODE § 35-38-1-7.1(b)(12) (2018).  
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protections be expanded under Indiana law. Evidence indicates that overdose immunity laws correlate 
to lower rates of opioid-overdose mortality.64 
Legislative efforts to expand access to overdose intervention drugs in Indiana are relatively recent. 
Research has yet to indicate that the average bystander in an overdose situation will have naloxone on 
hand. Thus, linking immunity in a drug overdose situation severely limits the number of applicable 
overdose situations and does not eliminate the fear of criminal liability for individuals present during the 
overdose situation.  
Indiana’s immunity does not extend to the individual who is in need of medical assistance. Reports 
suggest bystanders are often reluctant to seek emergency services for individuals in the overdose 
situation for fear of not only their own criminal liability but also the criminal liability of those 
experiencing the overdose.65 Several states, including New Mexico and Washington, have enacted 
broader drug overdose immunity laws to provide protections to both bystanders and the individual in an 
overdose situation.66  
While Indiana’s immunity includes protections from drug possession and drug paraphernalia charges,67 
it does not extend to parole or probation violations, alcohol related offenses, or to the execution of 
warrants. One interviewee indicated that, even if law enforcement officers choose not to arrest 
someone for possessing drug paraphernalia, officers would be obligated to follow-up if there was an 
outstanding warrant against that person. 
2. Drug Paraphernalia Laws  
Indiana law makes it unlawful to possess drug paraphernalia, instruments, devices, or other objects 
intended for introducing, testing, or enhancing a controlled substance.68 It also prohibits providing 
another individual with drug paraphernalia.69 Syringes used to inject an illegal drug can be considered 
drug paraphernalia under Indiana law.70 Violation of the drug paraphernalia law is considered a 
misdemeanor.71 However, Indiana law elevates the offense to a felony if the paraphernalia is a syringe 
or needle.72 Individuals distributing syringes as part of a syringe exchange program are exempt from 
criminal liability under Indiana’s distribution of drug paraphernalia73 as are bystanders possessing drug 
                                                          
64 See, e.g., Chandler McClellan et. al, Opioid-overdose laws association with opioid use and overdose mortality, Addictive 
Behaviors, (forthcoming 2018); Corey Davis, Damika Webb, & Scott Burris, Changing Law From Barrier to Facilitator of Opioid 
Overdose Prevention, 41 J. LAW MED ETHICS 33 (2013). 
65 Preventing the Consequences of Opioid Overdose: Understanding 911 Good Samaritan Laws, SAMHSA’S CENTER FOR THE 
APPLICATION OF PREVENTION TECHNOLOGIES (November 8, 2017), available at https://iu.app.box.com/file/267744244520. 
66 See, e.g., N. M. Stat. Ann. § 30-31-27.1 (2018); WASH. REV. CODE ANN. § 69.50.315 (2018). 
67 IND. CODE § 16-42-27-2(h) (2018).  
68 IND. CODE § 35-48-4-8.3(b) (2018).  
69 IND. CODE § 35-48-4-8.5 (2018).  
70 See, e.g., Perkins v. State, 57 N.E.3d 861 (Ind. Ct. App. 2016); Sluder v. State, 997 N.E.2d 1178 (Ind. Ct. App. 2013); Moore v. 
State, 223 N.E.2d 899 (Ind. 1976). See, also, Cooper v. State, 357 N.E.2d 260 (Ind. Ct. App. 1976) (stating that the drug 
paraphernalia can be based on the intent of use).   
71 IND. CODE § 35-48-4-8.3(b) (2018). 
72 IND. CODE § 16-42-19-18 (2018).  
73 IND. CODE § 35-48-4-8.5(c)(3), (4) (2018).  
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paraphernalia during an overdose emergency under Indiana’s overdose immunity law described 
above.74  
Several interviewees identified Indiana’s drug paraphernalia law as a legal barrier to an effective 
response in the substance use crisis. One interviewee in law enforcement indicated that criminal liability 
under such laws served as leverage to encourage persons with SUD to seek treatment or participate in 
drug court. However, another interviewee disputed this notion stating that this approach “hasn’t fixed 
[the SUD crisis].”  
Following the devastating HIV outbreak in southern Indiana due to sharing unsterile syringes for drug 
use, Indiana law now permits local governments to operate syringe exchange programs (SEPs).75 
Evidence strongly suggests that SEPs are an effective way to reduce disease transmission,76 link those 
with SUD to treatment and other services,77 and can be less costly than providing healthcare services for 
preventable diseases.78 While individuals distributing syringes through a SEP are exempt from criminal 
liability,79 those securing syringes from a SEP are not exempt from criminal liability under Indiana’s drug 
paraphernalia law. Conversely, North Carolina law allows for limited immunity for drug paraphernalia “if 
the person claiming immunity provides written verification that a needle, syringe, or other injection 
supplies were obtained from a needle and hypodermic syringe exchange program.”80 Drug 
paraphernalia laws that do not provide immunity to those securing syringes via SEPs can limit the 
efficacy of SEPs. One expert indicated that part of SEP success is based on a participant’s ability to feel 
safe while at the program, which might include safety from criminal prosecution.  
Multiple interviewees highlighted the discretion law enforcement possess regarding whether to arrest 
or charge individuals for possession of drug paraphernalia when they possess a syringe. One interviewee 
indicated that they generally prefer not to arrest individuals in such instances; however, this interviewee 
acknowledged that, in the field, law enforcement officers may also exercise their discretion to arrest 
someone for this crime.  
3. Safe Stations  
Safe Stations are an alternative strategy that some jurisdictions have implemented to link persons with 
SUD to care.81 For example, the Michigan State Police Department (MSP) has established an “Angel 
                                                          
74 IND. CODE § 16-42-27-2(g), (h) (2018). 
75 IND. CODE 16-41-7.5-1 et seq. (2018). 
76 See, e.g., Philip J. Peters, et. al., HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015, 375 NEW ENG. J. 
MED. 229, 237 (2016); Steffanie A. Strathdee & Chris Beyrer, Threading the Needle – How to Stop the HIV Outbreak in Rural 
Indiana, 373 NEW ENG.J. MED. 397, 398 (2015); Effectivness of Sterile Needle And Syring Programming in Reducing HIV/AIDS 
Among Injecting Drug Users, WORLD HEALTH ORGANIZATION (2014), available at www.who.int/hiv/pub/prev_care/effectiven 
esssterileneedle.pdf?ua=1; Don C. Des Jarlais et al., HIV Incidence Among Injecting Drug Users in New York City Syringe-
Exchange Programmes, 348 Lancet 987 (2016), available at https://www.ncbi.nlm.nih.gov/pubmed/8855855;  
Holly Hagan et al., Reduced Risk of Hepatitis B and Hepatitis C Among Injection Drug Users in The Tacoma Syringe Exchange 
Program, 85 Am. J. Public Health 1531 (1995), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1615682/.  
77S. A. Strathdee, et al., Needle-Exchange Attendance And Health Care Utilization Promote Entry Into Detoxification, 76 J. URBAN 
HEALTH 448 (1999), available at https://www.ncbi.nlm.nih.gov/pubmed/10609594.  
78 T. Q. Nguyen, et al., Syringe Exchange in The United States: A National Level Economic Evaluation of Hypothetical Increases in 
Investment, 18 AIDS BEHAV 2144 (2014), available at https://www.ncbi.nlm.nih.gov/pubmed/24824043.  
79 IND. CODE § 35-48-4-8.5(c)(3), (4) (2018). 
80 N.C. GEN. STAT. ANN. § 90-113.27 (2018).  
81 ‘Safe Stations’ Program Offers Path to Recovery for Opioid, Heroin Addicts, COUNTY NEWS (Sep. 18, 2017), 
www.naco.org/articles/‘safe-stations’-program-offers-path-recovery-opioid-heroin-addicts.  
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Program” in which individuals who seek addiction treatment can receive information and transportation 
to a treatment facility at any MSP post during business hours.82 Further, in East Manchester, New 
Hampshire, fire stations provide similar services twenty-four hours a day.83 To be eligible to participate, 
an individual must be eighteen years or older, regardless of whether they have health insurance or 
not.84 The city of East Manchester has experienced a drop in the number of overdoses since 
implementing the program.85 Additionally, the treatment facilities affiliated with the “Safe Station” 
program have reported that, of the more than one-thousand participants entering and exiting the 
program, 70 percent complete their treatment.86 One interviewee indicated that a safe stations might 
be an effective intervention in Indiana.  
C. Opportunities 
Based on the success of safe stations in other jurisdictions, Indiana entities should consider:  
• Repealing the requirement that bystander immunity be linked to the administration of overdose 
intervention drugs;  
• Extending immunity to include the individual needing medical assistance;  
• Extending immunity to include violations such as execution of warrants, parole/probation 
violations, and alcohol-related offenses;  
• Providing immunity to individuals possessing syringes secured from syringe exchanging 
programs;  
• Granting immunity to overdose victims for possession of drug paraphernalia; and 
• Implementing safe station programs.   
                                                          
82 Michigan State Police, MSP Angel Program, http://www.michigan.gov/msp/0,4643,7-123-72297_34040_77095-394452--
,00.html (last visited Mar. 25, 2018).  
83 Manchester Fire Department, Safe Station, https://www.manchesternh.gov/Departments/Fire/Safe-Station (last visited Mar. 
25, 2018).  
84 Spotlight: Manchester, NH Fire Department Safe Stations Program (April 2017), 
http://docs.wixstatic.com/ugd/bfe1ed_c2015ef58460406aa0dd166ece461f7e.pdf.  
85 Spotlight: Manchester, NH Fire Department Safe Stations Program (April 2017), 
http://docs.wixstatic.com/ugd/bfe1ed_c2015ef58460406aa0dd166ece461f7e.pdf.  
86 Spotlight: Manchester, NH Fire Department Safe Stations Program (April 2017), 
http://docs.wixstatic.com/ugd/bfe1ed_c2015ef58460406aa0dd166ece461f7e.pdf.  
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2. HEALTHCARE INTERVENTIONS 
A. Background 
Prior reports, including The Surgeon-General’s Report (2016),87 multiple interviewees from different 
domains, and our original research identified multiple and varied public health and healthcare delivery 
interventions to prevent or alleviate the consequences of SUD. In this section, we identify appropriate 
interventions and/or barriers to interventions. 
B. Findings 
Indiana policymakers have made several positive changes to health Interventions in Indiana. These 
include: 
• The Indiana State Department of Health (ISDH) has increased the availability of naloxone 
and removed barriers such as pre-authorization.88 
• The Indiana Family and Social Services Administration (FSSA) has successfully applied for an 
extension to the State’s Section 1115 Medicaid demonstration program, extending Medicaid 
coverage to those suffering from SUD for short-term residential stays in Institutions for 
Mental Diseases.89 Indiana’s Medicaid program now also reimburses all three evidence-
based drug treatments.  
• The State has opened90 or authorized the opening91 of additional treatment facilities. 
• There are ongoing initiatives led by the Chief Justice of the Indiana Supreme Court and her 
Office of Judicial Administration to train judges, prosecutors, public defenders, and 
probation officers in the evidence-base for Medication Assisted Treatment (MAT). 
• Improvements have been made regarding the availability of information about available 
inpatient treatment facilities through a partnership between Open Beds, FSSA, and Indiana 
2-1-192 
However, real or perceived barriers to effective interventions remain. Our interviewees and original 
research addressed the following policy issues and legal barriers: 
1. Syringe exchange program 
Earlier in this preliminary report, we present some detailed findings on harm reduction strategies, 
including legal barriers to the effective leveraging of syringe exchange programs and the relatively 
                                                          
87 Early Intervention, Treatment, and Management of Substance Use Disorders, in Facing Addiction in America: The Surgeon 
General’s Report on Alcohol, Drugs, And Health, 4-1 (2016), available at 
https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf.  
88 Save A Life: Help Prevent Overdose Deaths, INDIANA STATE DEPT. OF HEALTH, https://optin.in.gov/ (last visited Mar. 30, 2018). 
89 CMS Approval Letter to FSSA (Feb, 1, 2018), available at https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-
Topics/Waivers/1115/downloads/in/Healthy-Indiana-Plan-2/in-healthy-indiana-plan-support-20-ca.pdf.  
90 Scott L. Miley, Governor Announces Five More Opioid Treatment Programs in Indiana, THEHERALDBULLETIN.COM (Jul. 5, 2017), 
http://www.heraldbulletin.com/news/state_news/governor-announces-five-more-opioid-treatment-programs-in-
indiana/article_2edb9758-619d-11e7-b2b0-cbd8274307ef.html. 
91 House Enrolled Act 1007 (2018), available at https://iga.in.gov/legislative/2018/bills/house/1007#document-273dbd52. 
92Indiana Announces New Partnership to Connect Hoosiers with Drug Treatment, FSSA NEWS RELEASE (Mar. 15, 2015), available at 
http://www.in.gov/fssa/files/FINAL-OpenBeds-211-press-release.pdf.  
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narrow application of Indiana’s limited “Good Samaritan” safe harbor. Here, we examine harm 
reduction more generally in the context of the healthcare continuum of care. 
The State’s syringe exchange program (SEP) remains incoherent with major county-by-county variations. 
This is despite the clear evidence base for exchanges as recognized by, for example, the Surgeon-
General's Report (2016),93 their proven role in reducing the transmission of HIV/AIDS94 and overall cost-
effectiveness.95 Some of these variations may be reduced if the state increases education designed to 
reduce stigma and emphasize the medical pathology of SUD. 
There is strong evidence SEPs open a path to treatment and do not increase rates of addiction.96 
Implementation of syringe exchange programs also have been found to reduce the risk of needle stick 
injuries among law enforcement officers in the community.97 In addition, SEPs are safe places and a 
place of re-entry from the streets for those with SUD. One of our interviewees described SEPs as places 
where persons with SUD “get love for the first time in a long time… [someone says] I don’t want you to 
die!” From another interviewee, we learned of a white board in one SEP that simply read, “You Are 
Loved.” 
Policymakers should recognize the far broader role of syringe exchanges. In practice, syringe exchange 
programs are modest, but critically important healthcare facilities. They offer persons with SUD route to 
a safer life, the minimization of comorbidities such as HIV/AIDS or Hepatitis-C, treatment, and even 
recovery.98 They not only provide clean syringes and other preventive equipment, they also are a source 
of naloxone, HI/AIDS and Hepatitis-C testing, and information about Medicaid eligibility. Some SEP staff 
are health professionals, many others are “certified navigators.” However, although they account for so 
many primary interventions, syringe exchanges are barely integrated into the continuum of care. 
Neither is the knowledge base collected by the exchanges leveraged by policymakers. 
Although some stakeholders have endorsed trying Supervised (or Safer) Injection Facilities (SIFs),99 they 
remain highly controversial even in states that do not share Indiana’s historical and cultural values. 
However, there are far less controversial, intermediate programs, creating safe spaces additional to 
syringe exchanges where persons with SUD or concerned family members know they can find naloxone 
and a connection to treatment.100 Recognizing exchanges and other safe spaces as critical components 
of the SUD continuum of care and linking them to effective treatment resources seems to be overdue. 
                                                          
93 Early Intervention, Treatment, and Management of Substance Use Disorders, in Facing Addiction in America: The Surgeon 
General’s Report on Alcohol, Drugs, and Health, 4-1, 4-10 to 11 (2016), available at 
https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf. 
94 Don C. Des Jarlais, et al., HIV Incidence Among Injecting Drug Users in New York City Syringe-Exchange Programmes, 348 THE 
LANCET 987 (1996), available at https://www.sciencedirect.com/science/article/pii/S0140673696025366.  
95 T. Q. Nguyen, et al., Syringe Exchange in The United States: A National Level Economic Evaluation of Hypothetical Increases in 
Investment, 18 AIDS BEHAV. 2144 (2014), available at https://www.ncbi.nlm.nih.gov/pubmed/24824043.  
96 Steffanie A. Strathdee et al., Needle-Exchange Attendance And Health Care Utilization Promote Entry into Detoxification, 76 J. 
URBAN HEALTH 448 (1999), available at https://www.ncbi.nlm.nih.gov/pubmed/10609594.  
97 Samule L. Groseclose et al., Impact of Increased Legal Access to Needles And Syringes on Practices of Injecting-Drug Users 
And Police Officers--Connecticut, 1992-1993, 10 J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol 82 (1995). 
98 SYRINGE EXCHANGE PROGRAMS, AIDS WATCH (2015), available at https://www.aidsunited.org/data/files/Site_18/AW2015-
SyringeExchange_Web.pdf. 
99 Martha Bebinger, AMA Endorses Trying Supervised Injection Facilities, WBUR (June 16, 2017), 
http://www.wbur.org/commonhealth/2017/06/16/ama-supervised-injection-facilities-opioids. 
100 See e.g., Manchester, New Hampshire Safe Stations program discussed in the Harm Reduction section of this report. 
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2. Tertiary Interventions 
The typical tertiary interventions take place at Emergency Departments (EDs), with patients being 
delivered by EMS or law enforcement. One of our healthcare provider interviewees estimated that 40-
60% of those presenting at Emergency Departments with SUD had comorbidities, in particular mental 
health illnesses. Additionally, the criminal justice system is responsible for the initiation of tertiary 
interventions when, for example, judges make dispositions subject to treatment. For those arrested or 
convicted, jails or correctional facilities may be the site of tertiary interventions. Our interviewees and 
original research identified several issues that create barriers to effective interventions. 
A. Judicially-Ordered Interventions 
From both our interviewees and original research, we found there was still a major barrier to effective 
tertiary interventions--the lack of consensus around MAT as the evidence-based treatment of choice. 
One interviewee went further, expressing the opinion that increasingly, treatment options have been 
taken out of the hands of healthcare providers and given to judges. This is part of a national failure to 
provide a full range of evidence-based treatments to persons involved in the justice system.101 
Interviewees also were concerned about judicial tendencies in some Indiana courts to prefer unproven 
strategies and the relatively narrow range of treatments recommended from the bench. Concern also 
was voiced about what was seen as the growing influence of device and drug detailers on the judiciary. 
B. Availability and Quality within the Criminal Justice System 
Jails: Many of our interviewees expressed concern with the quantity and quality of treatment provided 
within the criminal justice system. One interviewee commented, “Anything is better than [what is 
provided in] jail!” A member of law enforcement informed us, “People don’t get help in jail.” Another 
told us, “The jail doesn’t have the capacity to fully address these individuals’ needs.” This problem has 
been exacerbated by a large increase in the number of persons with SUD being held in jails (some for 
extended periods of time) and we were told persons in jail on a “pretrial hold” “cannot get treatment at 
all.” The same interviewee explained, although some judges make their orders dependent upon the 
defendant undergoing treatment, these orders typically are made at the end of the case, by which time 
it may be too late. 
Department of Correction: Healthcare services provided to persons in Department of Correction (DoC) 
facilities have had something of a checkered history. For example, in 2016 the Department settled a 
long-standing class action lawsuit regarding the segregated confinement of seriously mentally ill 
prisoners, promising them “minimum adequate treatment.”102 Over the past two years, DoC has made 
significant changes to its intake screening protocols and adopted a new assessment tool for persons 
with SUD. This has been accompanied by changes in treatment protocols increasing the availability of 
                                                          
101 Noa Krawczyk et al., Only One in Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone 
Or Buprenorphine, 36 Health Aff. 2046 (2017), available at https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2017.0890.  
102 ACLU of Indiana, Indiana Protection & Advocacy Services Announce Settlement with Department of Correction (Jan. 27, 
2016), available at https://www.aclu.org/news/aclu-indiana-indiana-protection-advocacy-services-announce-settlement-
department-correction. 
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naltrexone and extended services.103 The new pre-release protocol is a 30-day course of naltrexone 
followed by a single-injection of its extended-release form (Vivitrol). The current DoC contract with its 
healthcare provider does not include broader, wrap-around services such as outpatient services at 
release. The current “state-of-the art” model for corrections-based treatment is Rhode Island. There, 
the Department of Corrections offers a full range of MAT to everyone in its prison system. Rhode Island 
has a far smaller prison population than Indiana and has an integrated jail-prison system in a single 
location.104 Notwithstanding it presents an integrated model worthy of study. 
Interviewees from provider and state agency domains noted a disconnect between DoC and managed 
care entities (MCEs) at release. Case managers work with persons about to be released to provide them 
with identification and other documentation and send a spreadsheet to the Division of Family Resources 
(DFR) to trigger a change in Medicaid status from “suspended” to “active.” Sometimes, that activation 
does not occur. Another issue identified is while the MCEs are notified of the identities of their 
reactivated patients, it can take considerably longer for their records or other information noting SUD to 
reach the MCEs so they can institute wraparound and treatment services during a critical time. 
We were told that there would be multiple benefits if a person’s Medicaid coverage was reactivated 30 
days prior to release. Information-sharing would improve and community care providers would be 
incentivized to make the transition smoother, while providing wraparound and treatment services. In 
2016, New York made a Section 1115 waiver request to institute such a program to pay for essential 
coordination and services prior to release.105 However, the proposal was dropped after the 2016 
election. 
3. Access to/Cost of Treatment 
SUD-related healthcare interventions are costly. The access of persons with SUD to treatment is, as with 
other healthcare services, a function of their insurance coverage. 
Private Health Insurance: As a consequence of the Affordable Care Act (ACA) (2010), individual health 
insurance policies offered on the exchanges must cover behavioral health treatment, mental and 
behavioral health inpatient services, and SUD treatment.106 Further, under the Mental Health Parity and 
Addiction Equity Act (2008), as amended by the ACA, individual, group health, and Medicaid managed 
care plans, must offer parity in their provision of mental health/substance use disorder benefits and 
medical/ surgical benefits. 
As a result, those with private insurance have reduced barriers to treatment. However, it is not 
unlimited, being subject to co-pays and “treatment days/stays” limitations. “Typical” private health 
insurance barriers also can arise, for example a treatment facility may be “out of network.” One 
                                                          
103 Alexis Dean & Stephanie Spoolstra, Addressing Addiction behind the Walls, Indiana Department of Correction (2016), 
available at https://www.in.gov/bitterpill/files/Addressing%20Addiction%20Behind%20The%20Walls%20-
%20Spoolstra%20and%20Dean.pdf.  
104 Andrew Joseph, One State Takes A Novel Approach to Opioid Addiction: Access to Treatment for All Inmates, STAT NEWS (Aug. 
3, 2017), available at https://www.statnews.com/2017/08/03/opioid-treatment-prisons/. 
105 Governor Cuomo Marks National Re-Entry Week By Seeking to Expand Medical Coverage For Individuals Leaving 
Incarceration (Apr. 29, 2016), available at https://www.governor.ny.gov/news/governor-cuomo-marks-national-re-entry-week-
seeking-expand-medical-coverage-individuals-leaving . 
106 For current benefits see Indiana 2017 EHB Benchmark Plan Information at M-13, https://www.cms.gov/CCIIO/Resources 
/Data-Resources/Downloads/IN-BMP.zip.  
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interviewee told us that when he arrived at a facility to arrange treatment for a family member, he was 
asked for a five-figure sum in advance.  
Medicaid/HIP: The Indiana Medicaid population is approximately 1.4 million.107 A state government 
interviewee estimated that 100,000 (or 7%) suffered from SUD but volunteered that under-reporting 
made it likely that the number was roughly twice that (or 14%). Interviewees and our research suggest 
that aspects of the Indiana HIP program and its extension will have a disproportionately negative impact 
on those with SUD.  
Since 2015, Indiana’s Medicaid program has been working as a demonstration under a federally-granted 
Section 1115 waiver. Under the original waiver, Medicaid benefits were tiered; only the higher tier 
included vision and dental coverage and did not impose a co-pay for most services. To qualify for the 
higher tier, otherwise eligible persons had to contribute to a health savings account. In broad terms, 
failure to do so would move those at 100% Federal Poverty Level (FPL) or below to the lower benefits 
tier, while those above 100% FPL would not receive benefits, or if they stopped paying would be locked 
out of benefits for a period of time. 
One of our interviewees noted that this original version of HIP “leads with paperwork not treatment” 
and many patients with SUD and/or those with mental health comorbidities were unable to handle the 
monetary or administrative burdens associated with establishing HIP eligibility. Recently published 
research supports such a conclusion; 55% of those eligible to pay premiums (some 287,000 persons) 
failed to do so, either dropping down to the lower benefits tier (< 101% FPL) or never being enrolled or 
                                                          
107 Kaiser Family Foundation, Medicaid in Indiana (June 2017), http://files.kff.org/attachment/fact-sheet-medicaid-state-IN. 
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losing coverage (>100% FPL).108 “The top two reasons cited by people who never enrolled in or lost HIP 
2.0 coverage were affordability and confusion about the payment process.”109  
The 2018 extension to the Indiana Medicaid program includes additional potential barriers to Medicaid 
enrollment. For example, the extension approves a tobacco surcharge, a work requirement (beginning in 
2019), and more process requirements.110 Persons with SUD and co-morbidities such as mental illness 
will have difficulty meeting the accompanying administrative requirements. Frequently they are 
transients whose qualifying paperwork fails to reach them. Many fall in and out of relapse making 
regular employment problematic. The new program will be subject to the Americans with Disabilities 
Act, contains a SUD-exception from the work requirement, and a medical frailty care exception to 
lockout. However, it is unclear how these will operate and how substantiation burdens will fall on those 
with SUD. It is at least arguable these additional requirements will increase the barriers to healthcare 
among the poor and very poor in Indiana, and disproportionately impact persons with SUD and 
comorbidities such as mental health illnesses.111 
Uninsured Persons: We were told by multiple interviewees that for the many who could not afford 
treatment or were not covered by Medicaid or private health insurance, there were few options. For 
example, the only option in Marion County was the Salvation Army Harbor Light detoxification facility.112 
This seems particularly to be the case for persons with SUD re-entering society from DoC. 
4. Availability of Treatment 
Multiple interviewees noted a critical lack of treatment programs and facilities in Indiana. For example, 
one interviewee told us the only treatment facility in Marion County is working far over-capacity. 
Another interviewee told us this facility has a waiting list and generally lamented the lack of inpatient 
and outpatient treatment opportunities. Another interviewee who works with a large SUD population in 
another county simply said, “there is nowhere to send them,” noting 2-3 month waiting lists, and that 
most available programs were abstinence-only, remarking that such programs had very poor results. 
5. Post-Treatment Services 
Some of our interviewees mentioned the importance of post-treatment services to keeping persons 
with SUD from relapsing. However, we found little evidence that Indiana was making progress in the 
provision of interventions designed to support those in recovery and/or in re-entry from correctional 
                                                          
108 Robin Rudowitz, MaryBeth Musumeci & Elizabeth Hinton, Digging Into the Data: What Can We Learn from the State 
Evaluation of Healthy Indiana (HIP 2.0) Premiums, KAISER FAMILY FOUNDATION (March 2018), http://files.kff.org/attachment/Issue-
Brief-Digging-Into-the-Data-What-Can-We-Learn-from-the-State-Evaluation-of-Healthy-Indiana-HIP-20-Premiums. 
109Robin Rudowitz, MaryBeth Musumeci & Elizabeth Hinton, Digging Into the Data: What Can We Learn from the State 
Evaluation of Healthy Indiana (HIP 2.0) Premiums, KAISER FAMILY FOUNDATION, at 4 (March 2018), 
http://files.kff.org/attachment/Issue-Brief-Digging-Into-the-Data-What-Can-We-Learn-from-the-State-Evaluation-of-Healthy-
Indiana-HIP-20-Premiums. 
110 MaryBeth Musumeci, Robin Rudowitz, and Elizabeth Hinton, Approved Changes in Indiana’s Section 1115 Medicaid Waiver 
Extension, KAISER FAMILY FOUNDATION (Feb. 09, 2018), https://www.kff.org/medicaid/issue-brief/approved-changes-in-indianas-
section-1115-medicaid-waiver-extension/. 
111 Hannah Katch et al., Medicaid Work Requirements Will Reduce Low-Income Families' Access to Care and Worsen Health 
Outcomes, Center on Budget and Policy Priorities (Feb. 8, 2018), https://www.cbpp.org/research/health/medicaid-work-
requirements-will-reduce-low-income-families-access-to-care-and-worsen. 
112 Detox Treatment, THE SALVATION ARMY HARBOR LIGHT, http://corps.salvationarmyindiana.org/harborlight/detox/ (last visited 
Mar 26, 2018). 
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facilities. Rather, we were told of stigma and legal or practical barriers to accessing necessities such as 
housing and employment. 
Several interviewees discussed the lack of sober, safe, or supportive living environments. Indeed, overall 
there is a dearth of wrap-around services, recovery support services, and counselling. As is the case with 
tertiary interventions, some of our interviewees questioned the adequacy of the workforce being tasked 
with managing the Substance Abuse Crisis.  
C. Opportunities 
• Policymakers should recognize syringe exchanges and other safe spaces as critical components 
in the SUD continuum of care and provide resources to better integrate them with treatment 
and other services. 
• Improvement are urgently needed to provide evidence-based treatment to Indiana’s jail 
population. 
• As discussed earlier in this report, Care Coordination could play an outsize role in triggering 
earlier and/or more effective interventions. Similarly, providing basic wrap-around services to 
those in recovery or during re-entry, such as supportive housing, are a cost-effective method to 
reduce Indiana’s expenditures on treatment and incarceration. 
• Additional research is required to evaluate the Indiana workforce tasked with the crisis. Issues 
that require investigation include scope of practice issues, the number of navigators, counsellors 
needed to service the SUD populations, and the potential for an increased workforce to adopt 
innovative interventions based on telemedicine or mobile apps. 
• Indiana should look beyond existing healthcare intervention models and explore the potential 
for, say, county or regional rapid stabilization models of care. 
• During the opioid epidemic Indiana policymakers should explore how to reduce administrative 
barriers to receiving Medicaid services. 
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3. CARE COORDINATION AND WRAP-AROUND SERVICES 
A. Background 
Earlier, this report discussed healthcare interventions and argued that harm reduction, diagnosis, 
treatment, and adherence strategies should be viewed as a continuum of care requiring improvements 
to or an increase in services across that continuum. This section focuses more narrowly on handoffs 
between service providers across that care continuum and the barriers that hinder those strategies. 
Prior reports, including The Surgeon-General’s Report (2016),113 The President’s Commission (2017),114 
multiple interviewees from different sectors and expertise areas, and our original research strongly 
suggest the urgent need to address care coordination and provide wrap-around services. In this section, 
we address both care coordination (improved integration of clinical care) and wrap-around services 
(non-clinical services improve patient engagement and treatment compliance, including transportation 
and housing services). Our interviewees also informed us of broader coordination and infrastructure 
problems, one noting, 
This problem [the current opioid crisis] and other 21st century problems don’t really lend 
themselves to the independent infrastructure that … now exists. There needs to be 
more of an interdependent, more of a collaboration between entities … because so 
many organizations, domains are affected by this and the problem is there’s very little 
communication between the same agencies within a domain like medicine, let alone 
between agencies like DCS, medicine, judiciary, mental health… 
To a large extent, lack of care coordination or fragmentation of care are defining features of the U.S. 
healthcare system.115 The need for improved coordination frequently has been cited by organizations 
such as the National Academies of Science,116 the Agency for Healthcare Research and Quality,117 and 
the National Quality Forum.118 Successful care coordination has several key pillars, including “access to a 
range of health care services and providers,” effective communications and care plan transitions (hand-
offs) between providers, a focus on the patient’s needs, the communication of “clear and simple 
                                                          
113 Health Care Systems And Substance Use Disorders, in FACING ADDICTION IN AMERICA: THE SURGEON GENERAL’S REPORT ON ALCOHOL, 
DRUGS, AND HEALTH, 6-1 (2016), available at https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-
report.pdf.  
114 The President’s Commission on Combating Drug Addiction And The Opioid Crisis 79 (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018) (noting the role of care coordination in “Post-overdose ED-based engagement, service 
linkage, and ongoing support and service coordination by recovery coaches and other peer workers.”).  
115 See, e.g., The Promise of Care Coordination: Transforming Health Care Delivery, FAMILIES, USA (Apr. 2013), 
http://familiesusa.org/sites/default/files/product_documents/Care-Coordination.pdf.  
116 See, e.g., Improving Diagnosis in Health Care, THE NATIONAL ACADEMIES OF SCIENCES ENGINEERING MEDICINE (Sept. 22, 2015), 
http://www.nationalacademies.org/hmd/Reports/2015/Improving-Diagnosis-in-Healthcare.aspx.  
117 Care Coordination, AGENCY FOR HEALTHCARE QUALITY AND RESEARCH, https://www.ahrq.gov/professionals/prevention-chronic-
care/improve/coordination/index.html (last visited Mar. 30, 2018).  
118 Care Coordination Measures, NATIONAL QUALITY FORUM, http://www.qualityforum.org/ProjectDescription.aspx?projectID 
=73700 (last visited Mar. 30, 2018).  
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information that patients can understand,”119 and the effective use of health information 
technologies.120 
It is broadly recognized that many of the care coordination issues that present in the SUD context follow 
from the historic segregation of substance use diagnosis and treatment from mainstream healthcare 
delivery, with the former frequently thought of as social or criminal justice issues that should be dealt 
with by psychiatric hospitals or prisons.121 As we now know, persons suffering from SUD (and frequent 
co-morbidities such as mental health diseases) are particularly vulnerable populations that in practice 
require additional and particularly robust levels of care coordination. 
B. Findings 
Indiana’s response to the opioid epidemic has included several positive steps that should increase care 
coordination, including data initiatives underway at the Management Performance Hub122 and the 
statewide deployment of the OpenBeds program.123 
Notwithstanding, our interviewees and/or research identified the following lack of coordination issues 
that hamper effective diagnosis, treatment, care of those suffering from SUD in Indiana: 
• SUD treatment is not a “one-size fits all” model; different patients require different treatment 
environments and different treatments (including different drug-based treatments), placing a 
premium on ongoing monitoring and care coordination. 
• Diagnosis or even treatment for SUD patients are not end points; SUD patients require ongoing 
care, including counselling and the provision of wraparound services. 
• The treatment of SUD patients is disproportionally exacerbated by factors such as poverty, 
inadequate/unsafe housing or homelessness, domestic abuse, lack of transportation, and 
insufficient legal services. Well-funded, coordinated robust wrap-around services can combat 
these issues. 
• Indiana’s expanded Medicaid program (HIP) increases benefits “churn.” Eligible individuals 
either fail to enroll or, having enrolled fail to make a premium payment and are then (depending 
on their federal poverty level) locked out or moved to a lower coverage tier. The recent HIP 
extension invokes increased payments (a tobacco surcharge) and additional administrative 
requirements associated with timely renewal and community engagement may worsen these 
phenomena. 
• Given the vulnerable SUD population and its frequent overlap with other conditions such as 
mental illness, HIP Medicaid requirements such as premium payments, identification and other 
documentation are difficult to navigate without assistance from third-parties such as healthcare 
providers or life coach coordinators. The same is likely to be the case with future changes to HIP 
                                                          
119 What Is Care Coordination?, NEJM CATALYST (Jan. 1, 2017), https://catalyst.nejm.org/what-is-care-coordination/.  
120 Improved Care Coordination: The Need for Better Improved Care Coordination, HEALTHIT.GOV, 
https://www.healthit.gov/providers-professionals/improved-care-coordination (last visited Mar. 30, 2018).  
121 Health Care Systems And Substance Use Disorders, in FACING ADDICTION IN AMERICA: THE SURGEON GENERAL’S REPORT ON ALCOHOL, 
DRUGS, AND HEALTH, 6-1, 6-5 (2016), available at https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-
report.pdf. 
122 Management Performance Hub, STATE OF INDIANA, http://www.in.gov/mph/ (last visited Mar. 20, 2018).  
123 Kristen Swilley, Indiana Partners with OpenBeds to Make Rehab Accessible to All, WCPO CINCINNATI (Mar. 19, 2018), 
https://www.wcpo.com/news/state/state-indiana/indiana-partners-with-openbeds-to-make-sure-everyone-who-needs-rehab-
can-access-it.  
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such as community engagement certification. Given the applicability of the Americans with 
Disabilities Act to many, even most in the SUD population, Indiana’s demonstration program 
with regard to community engagement likely will require substantial carve-outs, potentially 
creating more indeterminacy as to Medicaid eligibility.  
• A disproportionally large percentage of those incarcerated in Indiana suffer from SUD. It is 
unclear whether there is effective clinical care coordination with, for example, Medicaid 
managed care entities (MCEs) occurs upon release. 
• There are very few wrap-around services that aid prisoner re-entry by, for example, assisting 
with serious issues such as employment and housing. Failure to acquire post-release 
employment exacerbates poverty and is a cause of recidivism.124 
• Although some providers and insurers have been able to provide limited wrap around services 
by providing direct financial assistance or employing “life” or “peer” coaches, these services are 
not reimbursed and are of uncertain sustainability. 
• Care coordination is hampered by poorly aligned patient privacy laws and regulations (discussed 
elsewhere in this report). 
• Care coordination requires vastly improved data-sharing across multiple stakeholders including 
clinical providers and state and local public health agencies. 
C. Opportunities 
If solving the care coordination problem was as easy as identifying it, fragmentation would not persist as 
a dominant problem in U.S. healthcare delivery. Equally, general healthcare delivery only recently has 
begun to integrate previously-siloed services such as mental health and substance-use. 
Notwithstanding, in the SUD context and on a shorter timeline there are several approaches that are 
worth exploring: 
• Although federal Medicaid rules do not allow for many wrap-around services, Indiana like any 
other state is free to fund these services and provide them through Medicaid, albeit without 
federal matching. If prisoner re-entry, safe and supportive housing, vocational services, etc., are 
allowed as reimbursable products then managed care and other reimbursed entities will have 
incentives to act as care coordinators and, importantly, can be subject to accountability. 
• Evaluate the provision of wrap-around services for 6-12 months for SUD individuals who 
successfully complete a treatment program. 
• Reduce the care coordination costs currently shifted to Medicaid providers by reexamining 
premium requirements, administrative requirements, and penalties such as lock-outs and 
negative HIP tiering for persons with SUD. 
• Demonstration projects have identified significant cost-savings in the Medicaid program from 
the use of care coordination interventions for those with chronic conditions.125 Recently, CMS 
has emphasized its increased flexibility in allowing states to experiment with new care models 
that can be funded with federal dollars.126 The primary vehicle for implementing such models 
are through the Section 1115 demonstration program that Indiana has now twice successfully 
                                                          
124 Adam Looney & Nicholas Turner, Work and Opportunity Before and After Incarceration, THE BROOKINGS INSTITUTION (Mar. 
2018), available at https://www.brookings.edu/wp-content/uploads/2018/03/es_20180314_looneyincarceration_final.pdf.  
125 See, e.g., Jingping Xing, Candace Goehring, & David Mancuso, Care Coordination Program for Washington State Medicaid 
Enrollees Reduced Inpatient Hospital Costs, 34 HEALTH AFFAIRS 653 (2015), available at https://www.healthaffairs.org/doi/abs 
/10.1377/hlthaff.2014.0655?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed.  
126 See, e.g., Dear Governor Letter from Thomas E. Price and Seema Verma, U.S. Dept. of Health and Human Services, 
https://www.hhs.gov/sites/default/files/sec-price-admin-verma-ltr.pdf.  
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leveraged. Indiana should consider making additional waiver requests to provide care 
coordination services and other wrap-around services. 
• Indiana should fund its own demonstration projects to examine novel approaches to providing 
coordinated are for the SUD population and evaluate their suitability in the Indiana context. 
Examples include: 
a. A “hub and spoke” model such as that used by Vermont’s Care Alliance for Opioid 
Addiction.127 This uses a managed care to expand MAT using an integrated model 
consisting of residential methadone treatment “hubs” and buprenorphine outpatient 
“spokes.” The “spokes” also include home health and wrap-around services. 
b. The optional Medicaid State Plan benefit under the Affordable Care Act of 2010, Section 
2703. This allows for states to establish “Health Homes” to coordinate care for people 
with Medicaid who have chronic conditions such as substance abuse and mental health 
illnesses. 
• Indiana should recognize that whatever the policy benefits of new reforms of HIP eligibility and 
maintenance of benefits are in regard to the general Medicaid population, those same reforms 
may cause a disproportionate reduction of services for those with SUD and co-morbidities such 
as mental health illnesses. Indiana should examine the feasibility of delaying the introduction of 
its eligibility and maintenance of benefits reforms as they apply to this vulnerable population 
until the substance use crisis shows signs of abatement. 
• Medicaid services should be reinstated for individuals 30 days prior to their release from 
corrections.128 This would enable improved, coordinated clinical hand-offs to Medicaid providers 
and the opportunity for community-based providers to provide wraparound services (such as 
finding safe and supportive housing) during the critical post-release period of time. 
  
                                                          
127 The Care Alliance for Opioid Addiction, VERMONT DEPT. OF HEALTH, http://www.healthvermont.gov/response/alcohol-
drugs/treating-opioid-use-disorder.  
128 Governors' Recommendations for Federal Action to End the Nation’s Opioid Crisis, NATIONAL GOVERNORS ASSOCIATION, 5 (Jan. 18, 
2018), available at https://www.nga.org/files/live/sites/NGA/files/pdf/2018/OGR/NGA%20Recommendations%20for%20 
Federal%20Action%202018.pdf.  
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4. DRUG TAKE BACK PROGRAMS 
A. Background 
Prescription drug diversion was a key accelerant in the rise of the Substance Abuse Crisis, and remains a 
prime source of misused opioids.129 The National Center on Addiction and Substance Use estimates that 
at least three of every five prescribed pills are not consumed by the recipient of the prescription,130 and 
the National Institutes of Health (NIH) estimates five out of every seven diverted prescription drugs are 
obtained from a friend or a relative.131 Research has shown that those prescribed opioids frequently do 
not recall receiving information about proper storage and/or disposal of leftover medications when they 
acquire their prescriptions.132 Programs promoting secure storage and disposal of prescription opioids, 
including drug take back programs, are an important means through which to reduce the diversion and 
misuse of prescription drugs. 
Indiana law authorizes (it does not mandate) the establishment and implementation of local drug take 
back programs,133 and ninety of Indiana’s ninety-two counties have at least one drug take back program. 
Such programs are often located at local police departments. The U.S. Department of Justice and Drug 
Enforcement Administration operate a web site that allows individuals to search for controlled 
substance public disposal locations by zip code,134 and Indiana’s state government web site offers 
further public guidance on safe drug and paraphernalia disposal.135 The President's Commission on 
Combating Drug Addiction and the Opioid Crisis encourages expansion of state take back efforts through 
the establishment of year-round take back sites at hospitals and clinics with onsite pharmacies.136 
Current Indiana law authorizes the Indiana Board of Pharmacy to oversee drug take back program 
implementation. That said, there are no obligations to fund such programs under state law. Current 
federal law helped to establish two national “take back days” to take place in the spring and fall of each 
year, and the Drug Enforcement Agency encourages communities to partner with area law enforcement 
on such events.137 
                                                          
129 Alexandra B. Collins, et al., Harnessing the Language of Overdose Prevention to Advance Evidence-Based Responses to The 
Opioid Crisis, 55 INT. J. DRUG POLICY 77 (2018), available at https://www.ncbi.nlm.nih.gov/pubmed/29524736.  
130 The National Center on Addiction and Substance Abuse, Ending the Opioid Crisis: A Practical Guide for State Policymakers 
(2017), available at https://www.centeronaddiction.org/addiction-research/reports/ending-opioid-crisis-practical-guide-state-
policymakers.  
131 Renee C. B. Manworren & Aaron M. Gilson, CE: Nurses’ Role in Preventing Prescription Opioid Diversion, 115 AM. J. NURS. 34 
(2015), available at https://journals.lww.com/ajnonline/Fulltext/2015/08000/CE___Nurses__Role_in_Preventing_Prescription. 
21.aspx.  
132 Alene Kennedy-Hendricks, et al., Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US 
Adults, 176 JAMA INTERN. MED. 1027 (2016), available at https://jamanetwork.com/journals/jamainternalmedicine/full 
article/2527388.  
133 Ind. Code § 25-26-23-5 (2017). 
134 Controlled Substance Public Disposal Locations - Search Utility, https://www.in.gov/idem/recycle/2343.htm (last visited Mar. 
29, 2018).  
135 Controlled Substance Public Disposal Locations - Search Utility, https://www.in.gov/idem/recycle/2343.htm (last visited Mar. 
29, 2018).  
136 The President’s Commission on Combating Drug Addiction And The Opioid Crisis 56 (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018).  
137 Controlled Substance Public Disposal Locations - Search Utility, https://www.in.gov/idem/recycle/2343.htm (last visited Mar. 
29, 2018).  
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B. Findings 
While national programs may help remove unused prescriptions from the community – the DEA reports 
they have collected more than 456 tons of unused medication through these efforts138 – several 
critiques arise. In the interest of maintaining the confidentiality of the person returning the medications, 
national take back events prohibit inspection and analyzation of materials returned to take back 
programs. DEA-sponsored take back events prohibit disposal of illicit drugs or controlled substances 
possessed illegally, and law enforcement is required to be involved in the take back events. 
Consequently, individuals wishing to dispose of illicit drugs or controlled substances obtained illegally, or 
those wishing to avoid a law enforcement interaction, would be unable to participate in DEA national 
drug-tack back events. Because there are only two events per year (one in the spring and one in the fall), 
there are several months between events during which unused controlled substances may accumulate 
in the community.  
Research also indicates that individuals appear only to be willing to travel up to six miles to participate in 
a drug take back program.139 While interviewees indicate that some communities have initiated local 
take back programs, it is unlikely that community access to such programs is uniform statewide. Finally, 
the President's Commission on Combating Drug Addiction and the Opioid Crisis encourages expansion of 
state take back efforts through the establishment of year-round take back sites at hospitals and clinics 
with onsite pharmacies.140 
C. Opportunities 
 
• Indiana and local communities should encourage and increase their support for the 
development and implementation of more flexible local take back programs that would expand 




                                                          
138 K. I. Stoddard, et al., Investigating Research Gaps of Pharmaceutical take back Events: An Analysis of take back Program 
Participants’ Socioeconomic, Demographic, and Geographic Characteristics and the Public Health Benefits of Take Back 
Programs, 59 ENVIRONMENTAL MANAGEMENT 871 (2017), available at https://link.springer.com/article/10.1007/s00267-017-0834-3.  
139 K. I. Stoddard, et al., Investigating Research Gaps of Pharmaceutical take back Events: An Analysis of take back Program 
Participants’ Socioeconomic, Demographic, and Geographic Characteristics and the Public Health Benefits of Take Back 
Programs, 59 ENVIRONMENTAL MANAGEMENT 871 (2017), available at https://link.springer.com/article/10.1007/s00267-017-0834-3.  
140 The President’s Commission on Combating Drug Addiction And The Opioid Crisis 56 (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018).  
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5. PATIENT PRIVACY PROTECTIONS 
A. Background 
Prior reports, including The President’s Commission, 2017,141 multiple interviewees from different 
domains, and original research strongly suggest a critical lack of alignment between the general medical 
privacy rules and those that apply to SUD patients. 
Consistently, informants suggested that clinical and social determinants data were deficient regarding 
persons with a SUD. Some informants complained about the absence of data or its poor quality. Others 
voiced concerns about a lack of clinical data-sharing and/or its interoperability. One serious legal barrier 
frequently mentioned was the lack of alignment between the federal privacy protections relating to 
medical records generally and those applying to substance use records. 
The HIPAA Federal Privacy Rule applies to all patients in most traditional healthcare environments.142 
HIPAA privacy also applies to patients being treated for substance use or mental health issues. HIPAA 
permits broad data-sharing between providers without requiring any patient consent.143 The Privacy 
Rule does not contain any provisions specific to substance use patients. However, the Privacy Rule does 
contain a special rule relating to some physician-documentation of mental health treatments. This 
“psychotherapy notes” exception creates a minor exception to the sharing of encounter information or 
“process notes” as distinct from typical clinical records.144 
The Confidentiality of Alcohol and Drug Abuse Patient Records rule, often referred to as 42 CFR Part 2 
(or just “Part 2”), provides an additional layer of confidentiality for the records of SUD patients.145 Part 2 
applies to federally-assisted programs that provide SUD programs that diagnosis, treat, or refer. Part 2 
can apply to personnel or a unit contained within a general medical facility. Historically, Part 2 has 
required an additional, highly specific consent from the patient before SUD records may be shared. In 
2017, the Substance Abuse and Mental Health Services Administration (SAMHSA) updated Part 2 
including some changes to the consent process.146 The updated consent provisions allow for a limited 
“general” consent contained in the “To Whom” section of the consent, under which a SUD patient may 
designate certain providers to receive certain, specified SUD information.147 Technically, the new 
consent rules operate quite differently from HIPAA and bring with them distinct accountability, 
research, and other provisions. Although the updated disclosure rule does include a new “medical 
emergency” exception,148 even that is not as permissive as the equivalent HIPAA approach. In 2018, 
SAMHSA revisited some of these issues but again declined to further align HIPAA and Part 2 
                                                          
141 The President’s Commission on Combating Drug Addiction And The Opioid Crisis 121-22 (Nov. 1, 2017), Office of National 
Drug Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018). 
142 45 C.F.R. §§ 160, 162, and 164 (2018). 
143 45 C.F.R. § 164.506 (2018). 
144 45 C.F.R. §§ 164.501, 164.508(a)(2) (2018). 
145 See, Confidentiality of Substance Use Disorder Patient Records, 42 C.F.R. Part 2 (2018). 
146 Confidentiality of Substance Use Disorder Patient Records, 82 Fed. Reg. 6052 (Jan. 18, 2017). 
147 42 C.F.R. §§ 2.31, 2.33 (2018). 
148 42 C.F.R. § 2.51 (2018). 
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provisions.149 To further complicate matters some States have passed substance use-specific privacy 
laws.150 
B. Findings 
The differential approach to protecting SUD records is blamed for inadequate integration of full SUD 
patient data in electronic health records (EHRs), the exclusion of SUD records from statewide sharing 
through Health Information Exchanges, the perpetuation of stigma by treating SUD patients differently, 
and the exclusion of SUD patients from potentially beneficial research based on EHR data.151 
Interviewees from more than one domain told us that greatest burdens are placed on emergency 
departments and primary healthcare providers who are called upon to care for SUD patients but without 
access (or at least easy access) to relevant medical records. 
As a matter of policy our literature searches and interviewees were in general agreement that the 
treatment of SUD (and mental health co-morbidities) must be normalized or mainstreamed. If our 
healthcare delivery is to move to a position where SUD is treated as a mainstream disease, then 
segregation of data between SUD populations and other populations should be removed. Indeed, there 
is some evidence that patients with a substance use history unknown to treating physicians have been 
put at risk by opioid prescribing.152 Indeed, one of our interviewees described non-aligned privacy rules 
as “an albatross,” and compared the resultant delays caused in treating opioid patients as involving risks 
similar to delays in treating trauma patients. 
Continued data segregation has been justified on the grounds that such data are particularly sensitive 
and that there has been a history of discrimination against SUD patients. For example, The Surgeon-
General’s Report noted, “Currently, persons with substance use disorders involving illicit drugs are not 
protected under anti-discrimination laws, such as the ADA.”153 This is partially correct, although SUD is 
recognized by the ADA as a disability, protection is lost if the person is “currently engaging in the illegal 
use of drugs.”154 As noted by SAMHSA, disclosure of SUD information can “lead to a host of negative 
consequences, including: Loss of employment, loss of housing, loss of child custody, discrimination by 
medical professionals and insurers, arrest, prosecution, and incarceration.”155 One of our interviewees 
noted that opioid patients are particularly fearful of information about their illness being shared with 
law enforcement and corrections, but less concerned about data sharing between providers. 
                                                          
149 Confidentiality of Substance Use Disorder Patient Records, 83 Fed. Reg. 239, 241 (Jan. 3, 2018). 
150 See e.g., CAL. HEALTH & SAFETY CODE § 11845.5 (West 2018); see generally RTI INTERNATIONAL, BEHAVIORAL HEALTH DATA EXCHANGE 
CONSORTIUM (2014) (at bequest of U.S. Dept. of Health and Human Services), available at https://www.healthit.gov/sites/ 
default/files/bhdeconsortiumfinalreport_06182014_508_compliant.pdf. 
151 Frakt, A. B., Bagley, N. (2015). Protection or harm? Suppressing substance-use data. NEJM, 372, 1879-188 
152 Constance M. Weisner et al., Trends in Prescribed Opioid Therapy for Non-cancer Pain for Individuals with Prior Substance 
Use Disorders, 145 PAIN, 287 (2009), doi:10.1016/j.pain.2009.05.006. 
153 Health Care Systems And Substance Use Disorders, in FaCING ADDICTION IN AMERICA: THE SURGEON GENERAL’S REPORT ON ALCOHOL, 
DRUGS, AND HEALTH 6-1, 6-34 (2016), available at https://addiction.surgeongeneral.gov/sites/default/files/chapter-6-health-care-
systems.pdf.  
154 42 U.S.C. § 12114(a) (2017); see also, 42 U.S.C. § 12111(6) (2017). 
155 Confidentiality of Substance Use Disorder Patient Records, 82 Fed. Reg. 6052, 6053. For strong defenses of Part 2, see Paul 
N. Samuels & Patty McCarthy Metcalf, Relaxing Patient Privacy Rules Would Worsen the Opioid Epidemic, STAT NEWS (Nov. 24, 
2017), https://www.statnews.com/2017/11/24/opioid-epidemic-patient-privacy/; Karla Lopez & Deborah Reid, Discrimination 
Against Patients With Substance Use Disorders Remains Prevalent And Harmful: The Case For 42 CFR Part 2, HEALTH AFFAIRS BLOG, 
(Apr. 13, 2017), https://www.healthaffairs.org/do/10.1377/hblog20170413.059618/full/.  
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This is also an area adversely affected by perceived barriers. In  addition to the lack of alignment 
between the HIPAA Privacy Rule and Part 2, specific provisions of the HIPAA Privacy Rule are cited by 
providers as reasons not to share patient information even when there is no real legal barrier. For 
example, one interviewee noted that HIPAA’s very limited “psychotherapy notes” exception discussed 
above can result in blanket refusals to share mental health information. 
C. Opportunities  
This is not a newly identified problem and there have been unsuccessful attempts to pass legislation to 
provide regulatory authority to better align the rules.156 As HHS rolls out regulations and policies 
authorized under the 21st Century Cures Act to promote interoperability,157 discourage “information 
blocking,”158 and establish a Trusted Exchange Framework159 more and improved clinical sharing 
inevitably will result and may, in the future, lead to some consensus on how to proceed with the 
differential laws. 
However, the current barriers to sharing SUD information (both real and perceived) must be addressed 
on a far shorter timeline. Waiting for a political consensus to develop that would abandon the disparate 
federal protections is infeasible. Rather, the issue must be engaged at the level of transparent, 
actionable regulatory guidances. 
HHS’s Office of Civil Rights (OCR) has published FAQs encouraging sharing and, more recently issued a 
“clarifying” Opioid Crisis Guidance that notes the flexibility in the HIPAA rule that permits providers to 
disclose information to families in dangerous or emergency situations and that a patient’s personal 
representative (recognized as such by state law) has the same rights as the patient.160 However, the 
Guidance does not address the relationship between HIPAA and the more stringent Part 2. Equally, 
SAMHSA has issued a FAQ on the interrelationship of Part 2 and Health Information Exchange.161 This 
dichotomous approach is clearly insufficient. 
HHS stakeholders (ONC, SAMHSA, and OCR-Civil Rights) should be instructed to coordinate their work 
and publish detailed and comprehensive joint guidances for providers, health information exchanges, 
and patients. These guidances should at the least: 
• Clarify the limited role of the “psychotherapy notes” provision and instruct providers that it 
does not justify a refusal to share substance use or mental health records. 
• Clarify in detail how the “emergency” carve-outs in the two regulations operate and provide 
detailed instructions on how to navigate them and document interventions. 
                                                          
156 E.g., Helping Families in Mental Health Crisis Act of 2016, H.R. 2646, 114th Cong. (2016); Overdose Prevention and Patient 
Safety Act of 2017, H.R. 3545, 115th Cong. (2017). 
157 42 U.S.C. § 300jj (2017). 
158 42 U.S.C. § 300jj-52(a) (2017). 
159 OFFICE OF THE NAT’L. COORDINATOR FOR HEALTH INFORMATION TECHNOLOGY, DRAFT TRUSTED EXCHANGE FRAMEWORK (2018), available at 
https://www.healthit.gov/sites/default/files/draft-trusted-exchange-framework.pdf  
160 HHS Office for Civil Rights Issues Guidance on How HIPAA Allows Information Sharing to Address the Opioid Crisis, HHS.GOV 
(Oct. 27, 2017), https://www.hhs.gov/about/news/2017/10/27/hhs-office-civil-rights-issues-guidance-how-hipaa-allows-info-
sharing-address-opioid-crisis.html. 
161 LEGAL ACTION CENTER, APPLYING THE SUBSTANCE ABUSE CONFIDENTIALITY REGULATIONS TO HEALTH INFORMATION EXCHANGE (HIE) (2010) (at 
bequest of U.S. Dept. Health and Human Services), available at https://www.samhsa.gov/sites/default/files/faqs-applying-
confidentiality-regulations-to-hie.pdf. 
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• Identify and promote specific, lawful data-sharing frameworks and technical workflows that 
handle the different consent provisions and minimize the barriers caused by the differential 
protections. This likely will require a rapid consultation process with EHR vendors to incorporate 
these into their software. The goal of this process should be to design workflows that, in 
practice, allow clinicians to treat patients with SUD without concerns over compliance with 
differing regulatory systems. 
• OCR and SAMHSA should issue explicit joint enforcement guidance that minimize clinicians’ 
concerns over the legal implications of dealing with these privacy laws. 
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Substance use disorder is prevalent in our criminal court systems. According to the Bureau of Justice 
Statistics, 5% of the general population above the age of 18 is substance dependent, whereas “[m]ore 
than half (58%) of state prisoners and two-thirds (63%) of sentenced jail inmates me[e]t the criteria for 
drug dependence or abuse.”162 While a significant proportion of the population in the criminal justice 
system for drug-related offenses meet the clinical criteria for drug dependence or abuse, more than one 
out of every two persons in state prisons and jails for violent crimes, and two of every three persons in 
prison or jail for property-related crimes, also meet that definition. One interviewee involved in the 
criminal courts estimated almost all cases seen in a particular court were “drug cases,” as “between 85 
and 95 percent” of the thefts, shoplifting, prostitution, home invasions and other lower level felonies 
were committed in pursuit of a way to pay for the drugs the person needed to avoid withdrawal 
symptoms, with some arrestees having “three, four, or five” cases pending at the same time.163 
Numerous interviewees, including all involved with the court systems, spontaneously shared a similar 
belief to that expressed by one interviewee: “Everyone in the judicial system knows we cannot jail 
ourselves out of this situation.” 
B. Findings 
1. Sequential Intercept Model Criminal Justice Intercept Points for SUD Interventions (SAMHSA 2015) 
 
The Sequential Intercept Model is recommended in the research as a framework to move the 
management of mental health and substance use disorder concerns outside the traditional criminal 
justice system and into health care and support services in the community. According to the federal 
Substance Abuse and Mental Health Services Administration (SAMHSA), the model focuses on five 
“intercept” points where interventions are possible: (1) Law Enforcement; (2) Initial detention/first court 
appearance; (3) Jails/courts; (4) Reentry from detention into the community; and (5) Community 
corrections, probation, and parole.164 
                                                          
162 Jennifer Bronson et al., Drug Use, Dependence, And Abuse Among State Prisoners and Jail Inmates, 2007-2009, U.S. Dept. of 
Justice, at 1 (2017) available at https://www.bjs.gov/content/pub/pdf/dudaspji0709.pdf. 
163 See Pedro Mateu-Gelabert et al., Strategies to Avoid Opiate Withdrawal: Implications for HCV and HIV Risks, 21 THE 
INTERNATIONAL J. DRUG POLICY 179 (2010), available at http://doi.org/10.1016/j.drugpo.2009.08.007. 
164 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, MUNICIPAL COURTS: AN EFFECTIVE TOOL FOR DIVERTING 
PEOPLE WITH MENTAL AND SUBSTANCE USE DISORDERS FROM THE CRIMINAL JUSTICE SYSTEM, HHS Publication No. 
(SMA)-15-4929 (2015), available at https://store.samhsa.gov/shin/content/SMA15-4929/SMA15-4929.pdf.  
Intercept 1•Law Enforcement Intercept 2•First Detention or Court Appearance
Intercept 3•Jails/Courts Intercept 4•Community Reentry Intercept 5•Community Corrections, Probation, Parole
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2. Application of Sequential Intercept Model 
Strides have been made to implement evidence-based programs at many of the SAMHSA intercept 
points. Interviewees pointed to such programs as Crisis Intervention Teams for mental health services 
and the Deflection Team Model adopted in jurisdictions in other states for substance use disorder165 
(Intercept 1), and mental health, drug, and veterans courts (Intercept 3). In 2013, almost 26,000 
Hoosiers were admitted to substance use treatment programs; 47% of program referrals were from our 
criminal justice system.166  
Indiana also has begun a pilot program in three counties that would allow for involuntary commitment 
proceedings to be brought against persons with a substance use disorder and would allow a person 
revived with naloxone who has been charged with or convicted of narcotic possession to be enrolled in a 
diversion program.167 Many states are implementing such involuntary treatment laws; however, there is 
no evidence that they are more effective than non-voluntary treatment interventions.168 In addition to 
limited demonstration of effectiveness, questions concerning such programs arise about local capacity, 
reinforcement of substance use-related stigma, as well as how such interventions affect individual civil 
rights.169  
Intercepts 4 and 5, the periods when the person moves from detention back to the community, are 
points of extreme risk for persons with substance use disorder. The experience of our interviewees 
engaged with the courts and criminal justice system echoes the evidence from the research, “Prisoners’ 
reentry – their return to the community from prison – can be stressful as former inmates try to obtain 
housing, reintegrate into their families and communities, find employment, and gain access to health 
care.”170 The two weeks following release from prison is a period of particular vulnerability; a study from 
Washington state found prisoners were as much as 129 times more likely to die of a drug overdose 
during that time than those in the general population.171 Interviewees described the significant strides 
taken in the past two years by the Indiana Department of Correction to improve the addiction treatment 
                                                          
165 See, e.g., For Addicts And Their Friends, Families, and Caregivers, GLOUCESTER POLICE DEPT., http://gloucesterpd.com/addicts/ 
(discussing the Angel program) (last visited Mar. 20, 2018); Jessica Reichert, Fighting the Opioid Crisis through Substance Use 
Disorder Treatment: A Study of a Police Program Model in Illinois, ILLINOIS CRIMINAL JUSTICE INFORMATION AUTHORITY (Sep. 7, 2017), 
available at http://www.icjia.state.il.us/articles/fighting-the-opioid-crisis-through-substance-use-disorder-treatment-a-study-
of-a-police-program-model-in-illinois.  
166 HAROLD KOOREMAN & MARION GREENE, TREATMENT & RECOVERY FOR SUBSTANCE USE DISORDERS IN INDIANA, IND. UNIV. CTR. FOR HEALTH POLICY 
16-H80 (Lyndy Kouns ed., 2016), available at https://fsph.iupui.edu/doc/researchcenters/Treatment%20and%20Recovery%202 
016.pdf.  
167 Substance Abuse—Medical Care and Treatment—Opioid Treatment Pilot Program, 2017 Ind. Legis. Serv. P.L. 125-2017 
(S.E.A. 499) (West). 
168 D. Werb et al., The Effectiveness of Compulsory Drug Treatment: A Systematic Review, 28 The International J Drug Policy 1 
(2016), available at http://doi.org/10.1016/j.drugpo.2015.12.005.  
169 Christine Vestal, Support Grows for Civil Commitment of Opioid Users, THE PEW CHARITABLE TRUSTS (Jun. 15, 2017), available at 
http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/06/15/support-grows-for-civil-commitment-of-
opioid-users; Joseph Paul, Indiana's Controversial Plan to Keep Opioid Addicts Out of Jail or Cemetery, JOURNAL & COURIER (Oct. 
26, 2017), available at https://www.jconline.com/story/news/2017/10/26/new-program-lets-counties-use-involuntary-
commitment-laws-opioid-addiction/548074001/.  
170 Ingrid A. Binswanger, et al., Release From Prison--A High Risk of Death for Former Inmates, 356 N ENGL J MED 157, 157 
(2007), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836121/#!po=1.28205.  
171 Ingrid A. Binswanger, et al., Release From Prison--A High Risk of Death for Former Inmates, 356 N ENGL J MED 157 (2007), 
available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836121/#!po=1.28205.  
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and recovery services available to the incarcerated, including bolstering the evidence-informed 
treatments available to inmates preparing to reenter the community (Intercept 4).172  
Interviewees noted that while much of the current research and intervention efforts focus on the rise in 
use of opioids such as heroin and fentanyl, many Indiana communities continue to see populations with 
high usage rates of methamphetamine, cocaine, and other drugs as well. These interviewees also 
confirmed evidence found in the research that there remain significant gaps in, or barriers to, access, 
continuity, and availability of services for persons with substance use disorder in state criminal justice 
systems. Challenges noted include: (a) insufficiency of outpatient mental health and SUD treatment 
facilities, especially those providing Medication Assisted Treatment (MAT); (b) lack of reliable systems to 
identify where openings for care are available; (c) the need for further education across the judicial and 
criminal justice systems framing the Substance Abuse Crisis as a health issue, rather than exclusively a 
law and order issue, and the benefits and effectiveness of MAT as a part of treatment (especially in 
comparison to detox, abstinence, and/or counseling alone); (d) the affordability of services, with those 
in need of care frequently lacking the resources and/or insurance benefits to afford the costs associated 
with receiving or maintaining community-based services. As stated by one interviewee within the 
criminal justice system, “Most of whom we serve are indigent – any cost is an impediment” to their 
treatment and recovery. 
In addition, several interviewees noted the tension between criminal law, child welfare programs, 
landlords, and some employers and the use of Medication Assisted Treatment as part of community-
based recovery. Several of the medications used in Medication Assisted Treatment programs are 
opioids, therefore the presence of maintenance medications (such as methadone) in a person’s blood or 
urine sample may be treated by some actors within these programs the same way as if heroin or 
fentanyl were to be found, affecting the person’s ability to drive, maintain “clean” test samples, obtain 
or maintain both housing and employment. 
Drug courts are effective in reducing substance use and the likelihood of overdose for persons in the 
criminal justice system who have committed non-violent crimes, especially when compared to the 
outcomes for persons committing comparable crimes who are not diverted to the drug court system.173 
Indiana has a strong drug court system in place; those drug courts in place are running at or near full 
capacity, although some underserved areas of the state remain. The President’s Commission on 
Combating Drug Addiction and the Opioid Crisis strongly supports the drug court system, recommending 
in its final report all substance use-related violations of probation or parole be diverted to drug courts 
and states establish drug courts in every county in every state.174 The Commission notes, “The principal 
factors limiting drug court expansion are insufficient funding, treatment, and supervision resources, not 
a lack of judicial interest.”175 
                                                          
172 Addiction Recovery Services, Indiana Department of Corrections, available at http://www.in.gov/idoc/3490.htm.  
173 The President’s Commission on Combating Drug Addiction And The Opioid Crisis (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018).  
174The President’s Commission on Combating Drug Addiction And The Opioid Crisis 10 (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018).  
175 The President’s Commission on Combating Drug Addiction And The Opioid Crisis 73 (Nov. 1, 2017), Office of National Drug 
Control Policy, President’s Commission: Final Draft, WHITEHOUSE.GOV, https://www.whitehouse.gov/ondcp/presidents-
commission/ (last visited Mar. 26, 2018). 
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Indiana certified drug courts must follow the procedural and structural best practice standards 
promulgated by the National Association of Drug Court Professionals.176 While drug courts and other 
specialty diversion courts are worth highlighting for their effectiveness, interviewees note they are not 
for everyone and should not be seen as a cure all for the problems of substance use disorder related to 
criminal activity. Interviewees cite similar limits to the drug court system due to insufficient funding, 
treatment, and supervision as identified in the President’s Commission report. Interviewees also noted 
the following issues: (a) drug courts are not meant for all persons with substance use disorder concerns 
in the criminal justice system; (b) there is significant variation in entry standards across drug courts; (c) 
while all courts must permit program enrollees to access the evidence-based practice of MAT for 
substance use, interviewees note that courts vary in their relative MAT-friendliness, and communities 
vary on the type and availability of service provider partners and wrap around services. Furthermore, 
while research recognizes the most effective MAT approach will be customized to the particular 
patient,177 and treatments such as buprenorphine and methadone have been found in studies by other 
states178 to be far more cost effective than Vivitrol (long-acting, injectable naltrexone), some courts have 
demonstrated an explicit preference for one form of MAT over others,179 perhaps due in part to 
education efforts by drug manufacturers directed at judges.180 
Multiple interviewees discussed the challenges that have arisen in the wake of Indiana’s criminal code 
reform in 2015,181 which reclassified nonviolent offenses and shifted these low-level felony cases away 
from the state Department of Correction to local jails and community corrections and probation. Since 
the shift, there has been a rapid rise in the felony population in the jail system.182 The jail systems are 
not equipped, nor are they robustly funded, to offer substantive substance use disorder treatment 
services, especially in comparison to the state Department of Correction. Consequently, because of the 
lack of treatment during time in jail, many charged with or convicted of low level felonies may be at 
particularly high risk of overdose and death as they are left without the establishment of “warm 
handoffs” that can facilitate treatment uptake between jail and community providers. Interviewees 
noted the difficulty of identifying quality community-based treatment program openings (both inpatient 
and outpatient) from the bench and would welcome additional support for addressing substance use 
disorder through evidence-informed resources such as bench books.  
C. Opportunities 
                                                          
176 National Drug Court Institute, National Association of Drug Court Professionals, Adult Drug Court Best Practice Standards 
(Vol. I and II) (2013), available at https://www.ndci.org/resources/publications/standards/.  
177 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN., DEPT. HEALTH AND HUMAN SERVICES, IN BRIEF 8(1), ADULT DRUG COURTS AND 
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178Long-Acting Injectable Medications for Alcohol and Opioid Use Disorders: Benefit-Cost Findings, Washington State Institute 
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for-Alcohol-and-Opioid-Use-Disorders-Benefit-Cost-Findings_Report.pdf.  
179 Christian Sheckler, New Treatment Options Spring Up for Heroin, Opioids But Crisis Far from Over, SOUTH BEND TRIBUNE (Jun. 4, 
2017), https://www.southbendtribune.com/news/publicsafety/new-treatment-options-spring-up-for-heroin-opioids-but-
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180 Jake Harper, To Grow Market Share, A Drugmaker Pitches Its Product To Judges, NPR.ORG (August 3, 2017), 
https://www.npr.org/sections/health-shots/2017/08/03/540029500/to-grow-market-share-a-drugmaker-pitches-its-product-
to-judges. 
181 House Enrolled Act 1006 (2015), available at https://iga.in.gov/static-documents/2/1/b/8/21b8684f/HB1006.06.ENRH.pdf.  
182 Dave Stafford, Criminal Code Reform Packs Jails with Level 6 Felony Inmates, THE INDIANA LAWYER, (Sept. 20, 2017), 
https://www.theindianalawyer.com/articles/44852-criminal-code-reform-packs-jails-with-level-6-felony-inmates.  
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Continued improvement of the court-system response to the Substance Abuse Crisis would benefit from 
research in the following areas: 
• Assessment of the knowledge, attitudes, beliefs, and behaviors of those working in the court 
systems related to Medication Assisted Treatment and Substance Use Disorder more 
generally; 
• Evaluation of the variation in entry requirements for the state’s drug courts; 
• An updated assessment of the decade-old, limited outcomes evaluation of Indiana’s state 
drug courts; 
• The effectiveness of using the Indiana 2-1-1 system (or the expansion of the new 2-1-
1/OpenBeds program) to aid in identifying area inpatient and community-based treatment 
options for those with community-based sentences and/or probation; and, 
• Identification and evaluation of court policies addressing the interaction of judges with 
pharmaceutical and medical device representatives. 
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7. PROCEEDS FROM OPIOIDS LITIGATION 
A. Background 
Hundreds of lawsuits have been filed against prescription opioid manufacturers and other participants in 
the drug supply chain across federal and state courts across the country. Manufacturers of prescription 
opioids face suit on a variety of claims, including “design” allegations such as failure to include an 
antagonist ingredient, failure to warn about addiction risks, and misrepresentations about the drugs’ 
safety.183 Increasingly, plaintiffs are basing their claims on allegations that (1) manufacturers ignored 
signs of or failed to investigate suspiciously large orders, and (2) the pharmaceutical industry 
exaggerated the benefits of long-term use of opioid pain relievers, while minimizing their addictive 
risks.184 The pool of defendants also is increasing with, for example, intermediaries in the drug supply 
chain, such as pharmacy benefit managers, being added to the lawsuits.185 
More than 40 state attorney generals are either investigating186 or actively litigating these claims against 
participants in the drug supply.187 In addition, throughout the country, multiple cities, counties, and 
tribal nations have brought actions against those participants.188 In Indiana, at least ten cities, including 
Indianapolis, and several counties have filed such lawsuits.189 The state of Indiana has contracted with a 
national litigation firm to “bolster the state’s legal analysis and litigation experience in this complex area 
of opioid accountability.”190 The recently enrolled Indiana Senate Bill No. 188 requires a report from the 
Attorney-General not later than July 1, 2018 as to whether to join the litigation.191 
In December 2017, the United States Judicial Panel on Multidistrict Litigation consolidated most federal 
claims (already numbering over 400) in the Northern District of Ohio before US District Judge Daniel 
                                                          
183 Rebecca L. Haffajee & Michelle M. Mello, Drug Companies’ Liability for the Opioid Epidemic, 24 NEW ENGLAND J. MED. 377 
(2017). 
184 Andrew Kolodny, et al, The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction, 36 
ANNU. REV. PUBLIC HEALTH 559 (2015). 
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187 Overview of State Litigation to Combat the Opioid Epidemic, ASSOCIATION OF STATE AND TERRITORIAL HEALTH OFFICIALS (Feb. 22, 
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188 See, e.g., Mitch Smith & Monica Davey, With Overdoses on Rise, Cities and Counties Look for Someone to Blame, N.Y. TIMES 
(Dec. 20, 2017), https://www.nytimes.com/2017/12/20/us/opioid-cities-counties-
lawsuits.html?mtrref=www.google.com&auth=login-email; Native American tribes sue opioid manufactures, distributors, CBS 
NEWS (Jan. 9, 2018), https://www.cbsnews.com/news/native-american-tribes-sue-opioid-manufacturers-distributors/.  
189 See, e.g., Ryan Martin, Opioid epidemic: 10 Indiana Cities Suing Pharmaceutical Companies, INDYSTAR (Jan. 8, 2018), 
https://www.indystar.com/story/news/crime/2018/01/08/noblesville-sues-pharmaceutical-companies-seeking-relief-
incredible-harm-caused-opioid-epidemic/1012598001/; John Russell, Nearly a Dozen Indiana Communities Sue Opioid Industry 
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191 S.B. 188, 120th Gen. Assembly, – 2nd Reg. Sess. (Ind. 2018), available at 
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Polster.192 On March 1, 2018, the U.S. Department of Justice filed a statement of interest requesting 
Judge Polster to grant it time to consider whether the federal government would participate in the 
litigation,193 eventually deciding on an amicus relationship.194 Several settlement conferences have been 
scheduled and there are reports of ongoing settlement talks between the parties.195 Additionally, Judge 
Polster has informed the parties that he wants to see a settlement in 2018.196 Complications include 
dealing with unconsolidated suits filed in state courts and whether settlement funds also should be 
allocated among counties or cities that have not yet filed suit.197 
Although the plaintiffs have begun to calculate the losses caused to their budgets and communities and 
how the attorneys involved will be compensated and settlement negotiations continue,198 the need for 
public discussion on the use of potential settlement or litigation proceeds remains paramount. Indeed, 
“[e]xperience suggests that the challenge will be ensuring that the windfalls to state governments are 
not diverted to unrelated purposes.”199 
B. Findings 
In many ways, the opioid litigation is tracking the 1990s tobacco litigation initiated by state attorneys 
general against several major tobacco companies.200 The opioid litigation may face a similar challenge 
related to the use of any recovered funds. In November, 1998, the major tobacco companies and 
settling states entered into The Tobacco Master Settlement Agreement (MSA).201 Under the MSA, states 
will receive approximately $246 billion during the first 25 years of the settlement;202 thereafter, 
payments will continue in perpetuity. Indiana receives approximately $130 million each year.203 
Between 1998 and 2017, Indiana received approximately $2.4 billion.  
                                                          
192 In Re: National Prescription Opiate Litigation, MDL No. 2804, http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2804-
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The recitals under the MSA contained strong language suggesting the purpose of the settlement and the 
intended use of its proceeds by the states.204 However, the agreement contained no specific or detailed 
language requiring the States to use the proceeds for specific tobacco-related or public health purposes. 
In the intervening years it has become apparent that only a very small percentage of the settlement 
funds have been used to encourage smoking cessation or otherwise increase related public health. In 
2007, the U.S. Government Accounting Office found that, on average, states allocated 30 percent of 
their settlement moneys to healthcare (including funding Medicaid and making payments to providers) 
and 22.9 percent to cover budget deficits.205 Other uses included education and infrastructure projects, 
with only 3.5 per cent being used for tobacco control.206 One state even used $42 million to help 
modernize tobacco farmers.207 It is hard to argue with the conclusion that “MSA resources have been 
significantly diverted from tobacco control and treatment into other state policy activities.”208 
Indiana law directs all MSA funds to ISDH and, while requiring the department to develop a mission 
statement concerning prevention and reduction of tobacco use and products, does not direct how or 
what funds should be allocated.209 Indiana spent $5.9 million on tobacco prevention in 2017 and $7.5 
million in 2018.210 Even that latter figure is only 10 per cent of CDC’s recommended spend and is less 
than 3 percent of the tobacco industry’s marketing spend in Indiana for 2018 ($277.2 million).211 
Lawsuits brought against the opioid industry routinely reference the financial costs suffered by our 
communities. For example, the City of Indianapolis complaint requests compensation for “past and 
future costs to abate the ongoing public nuisance caused by the opioid epidemic [and] damages caused 
by the opioid epidemic” and a Defendant-funded “abatement fund” for the purposes of abating “the 
opioid nuisance.”212 However, this and other filed complaints generally lack any commitment to how 
such compensatory funds will be allocated. 
There are some positive signs that Indiana recognizes the moral imperative that opioid-derived funds 
should be used to ameliorate the harms caused by the crisis. For example, in 2016, then Attorney 
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General Zoeller made available $400,000 to equip first responders with naloxone.213 Importantly, those 
funds were financed from settlement funds received by the Attorney General because of off-label and 
deceptive marketing by pharmaceutical companies.214 
C. Opportunities 
• Indiana stakeholders should aggressively demand and support the inclusion of language in any 
opioids settlement that directs the majority of settlement funds to be spent on the treatment of 
those suffering from SUD, children born with Neonatal Abstinence Syndrome and, through 
spending on healthcare preventative services and improving the social determinants of health, 
the creation of healthier environments that will reduce the likelihood of future substance use 
outbreaks. 
• Indiana should signify a similar commitment to such uses of opioid settlement funds by passing 
legislation that commits the state to responsible and relevant “best practices” expenditures that 
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8. STIGMA 
Stigma is a dynamic multidimensional, multilevel phenomenon that occurs at three levels of society — 
structural (laws, regulations, policies), public (attitudes, beliefs, and behaviors of individuals and 
groups), and self-stigma (internalized negative stereotypes).215 
A. Background 
Issues related to mental health and substance use disorder historically have been stigmatized in our 
society. Research demonstrates myriad ways that negative attitudes, beliefs, and behaviors toward 
substance use disorder undermine the adoption, implementation, and effectiveness of evidence-based 
and evidence-informed policies to address the opioids crisis. Stigmatization, which can be found in laws 
and policies; attitudes, beliefs and behaviors; and in the ways one views one’s self, has been found to 
increase barriers to recovery and community integration, and decrease an individual’s pursuit of work 
and help.216 These research findings are reinforced by the comments made by multiple interviewees, 
who have experienced or witnessed the adverse effects that arise out of stigmatizing mental health 
and/or SUD-related concerns.  
As noted in the above quotation, stigma can present itself in the SUD crisis in various forms and 
permeates across the law and policy areas outlined above. Presentations include: (a) the framing of 
behaviors associated with substance use disorder and mental health concerns as the manifestation of 
individual moral failings, rather than as a health concern, medical illness, or symptoms of a brain 
disease217; and (b) the perception of management of substance use disorder as a binary state (that you 
are either “clean” of drugs or addicted, you demonstrate strength or weakness), rather than recognizing 
that substance use treatment218 and recovery219 may involve both setbacks and maintenance therapy. 
These and other manifestations of stigma contribute to the marginalization of our vulnerable fellow 
Hoosiers in need of treatment and recovery services. The consequences are significant: stigma is 
associated with a delay or resistance to seeking treatment, the underfunding of services related to SUD 
care, more punitive and unaccommodating treatment in the law and in enforcement via the criminal 
justice system, and denial or discouragement of access to resources, such as housing, employment 
protections, medication assisted treatment, and other evidence-based harm reduction services shown 
to reduce morbidity and mortality. 
B. Findings  
Interviewees shared an array of stigma-driven situations. One noted an unwillingness of some area 
pharmacies to carry naloxone because they did not want people with substance use disorder around 
                                                          
215 NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE, ENDING DISCRIMINATION AGAINST PEOPLE WITH MENTAL AND SUBSTANCE USE 
DISORDERS: THE EVIDENCE FOR STIGMA CHANGE 4 (2016). 
216 NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE, ENDING DISCRIMINATION AGAINST PEOPLE WITH MENTAL AND SUBSTANCE USE 
DISORDERS: THE EVIDENCE FOR STIGMA CHANGE 42-49 (2016). 
217 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN., DEPT. OF HEALTH AND HUMAN SERVICES, IN BRIEF 9(1), CHRONIC SUBSTANCE USE AND 
COGNITIVE EFFECTS ON THE BRAIN (2016), available at https://store.samhsa.gov/shin/content/SMA16-4973/SMA16-4973.pdf.  
218 Early Intervention, Treatment, and Management of Substance Use Disorders, in FACING ADDICTION IN AMERICA: THE SURGEON 
GENERAL’S REPORT ON ALCOHOL, DRUGS, AND HEALTH, 4-1 (2016), available at https://addiction.surgeongeneral.gov/sites/default/files/ 
chapter-4-treatment.pdf.  
219 Recovery: The Many Paths to Wellness, in FACING ADDICTION IN AMERICA: THE SURGEON GENERAL’S REPORT ON ALCOHOL, DRUGS, AND 
HEALTH, 5-1 (2016), available at https://addiction.surgeongeneral.gov/sites/default/files/chapter-5-recovery.pdf.  
Legal and Policy Best Practices in Response to the Substance Abuse Crisis 
55  |  April 26, 2018 
 
their facilities (an observation that appears to be paralleled in a recent study that found Indiana 
pharmacists in areas with higher rates of opioid overdose mortality 56% less likely to sell syringes 
without a prescription than in areas with lower mortality rates).220 Others noted “Not in My Back Yard” 
concerns arising related to siting of facilities for Medication Assisted Treatment or other harm reduction 
services, such as syringe exchange programs. One interviewee noted that no information is submitted 
into the INSPECT system concerning methadone prescriptions, casting its prescribing under a cloud. 
Some interviewees discussed the unwillingness of certain recovery programs, employers, and housing 
settings to accommodate individuals who use medications for treatment and recovery such as suboxone 
or methadone. Some interviewees, discussing probation and the criminal justice system, described 
setbacks in care being treated as intolerable; this resulted in reinstatement of sentences or expulsion 
from treatment programs rather than recognition that such incidents are unfortunate but foreseeable 
detours on the road to recovery. 
The rise in physician prescription of pharmaceutical opioids for outpatient pain management is 
frequently noted as a key contributor to the current crisis.221 Consequently, many policy initiatives 
adopted and proposed in response to the epidemic – including implementation of Prescription Data 
Monitoring Programs (PDMPs), introduction of treatment agreement regulations by the state medical 
board,222 implementation of professional education mandates, and establishment of opioid dose 
prescribing limits223 – have focused directly or indirectly on regulating how pain management is 
addressed in the physician-patient relationship. While aimed at public safety, such efforts may reinforce 
negative stigmas related to Substance Use Disorder for both patients and providers. For example, efforts 
to discourage aberrant, drug-seeking behavior, such as frequent screenings and pill counts, pain 
contracts, and/or narrow dosage or pill limits, may also discourage the pursuit of treatment by patients 
with genuine pain concerns. Furthermore, as noted by one interviewee: while physician and other 
healthcare provider behavior may have contributed to the current crisis, physician and other provider 
education and ongoing involvement is critical to efforts to implement evidence-informed responses.224  
Studies have shown that education campaigns can help decrease stigma associated with mental health 
and substance use disorder.225 As noted above, seeing these circumstances at base as health concerns 
rather than as moral failings reduces structural stigma, public stigma, and self-stigma. It also helps 
increase cross-sector collaboration (such as criminal justice, health care, and public health). Progress in 
these areas is being made. As noted optimistically by one interviewee, “People never talked about this 
stuff before” in multidisciplinary settings. The state’s new Next Level Recovery Website and “Know the 
O Facts” campaign226 can aid in the adoption of more supportive, less judgmental “person first” 
language when discussing the people and events associated with addiction, recovery, and treatment. 
                                                          
220 Beth E. Meyerson et al., Predicting Pharmacy Syringe Sales to People Who Inject Drugs, 56 INT. J. DRUG POLICY 46 (2018), 
available at https://doi.org/10.1016/j.drugpo.2018.02.024. 
221 SAM QUINONES, DREAMLAND (2015). 
222 Summer McGee & Ross D. Silverman, Treatment Agreements, Informed Consent, and the Role of State Medical Boards in 
Opioid Prescribing, 16 PAIN MEDICINE 25 (2015), available at https://doi.org/10.1111/pme.12580. 
223 See, e.g., INDIANA GUIDELINES FOR OPIOID PRESCRIBING IN THE EMERGENCY DEPARTMENT, IND. STATE DEPT. OF HEALTH, available at 
https://www.in.gov/isdh/files/Indiana_ER_Opioid_Prescribing_Guidelines.pdf (last visited March 25, 2018); CENTERS FOR 
MEDICARE AND MEDICAID SERVICES, IMPROVING DRUG UTILIZATION REVIEW CONTROLS (OPIOIDS), in 2019 MEDICARE ADVANTAGE AND PART D 
ADVANCE NOTICE PART II AND DRAFT CALL LETTER (Feb. 1, 2018), available at https://www.cms.gov/Newsroom/MediaReleaseDatabase 
/Fact-sheets/2018-Fact-sheets-items/2018-02-01.html.  
224 Sue Loughlin, Medical Practices Changing in Face of Opioid Crisis, INDIANA ECONOMIC DIGEST, March 19, 2018, available at 
http://indianaeconomicdigest.com/Main.asp?SectionID=31&SubSectionID=91&ArticleID=91547.  
225 National Academies of Sciences, supra note 1, at 69-92.  
226 Next Level Recovery, STATE OF INDIANA, http://www.in.gov/recovery/index.html, (last visited Mar. 25, 2018). 
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Campaigns that connect individuals and families with peer support, such as the Veteran’s Affairs Make 
the Connection website, can increase pursuit of care and build connections through shared community 
experiences. Increasing health professional education via continuing education programs and other 
professional in-service activities can help demystify issues related to pain, mental health, addiction and 
treatment.  
Several interviewees were optimistic about the effectiveness of education campaigns within their work 
environments that included the sharing of personal stories of the struggles of the participants, or of 
their friends and loved ones, with substance use disorder. As one interviewee stated, with the SUD crisis 
affecting so many communities, this is no longer an issue facing some nameless “drug addict,” but 
instead, “That's your uncle, cousin, friend.” These educational programs were especially useful in 
exploring the concepts of risk and protective factors associated with SUDs, increasing participant 
understanding of why some people struggle with addiction while others do not.227 They also may be 
useful in helping allay compassion fatigue among first responders,228 and in increasing self-care 
behaviors and resilience within these various high stress professions responding to the crisis. Finally, 
some interviewees described the positive impact of education efforts that made parallels between 
struggles with SUD and the onset and management of adult-onset diabetes, or access to treatment and 
recovery medications for SUDs to access to heart medications following cardiac arrest or insulin for 
diabetics.  
More effective than education alone in reducing stigma are initiatives that foster meaningful contact 
between those inside and outside the stigmatized population. A meta-analysis of 79 studies found that 
programs that engaged affected populations, who were able to share and personalize the information 
with their lived experiences, were twice as effective in improving attitudes and intended behaviors as 
education alone.229 This community engagement model has been highly successful in national programs 
delivering health services to vulnerable populations. For example, federal law requires that 51% of the 
members of governing boards of Federally Qualified Health Centers be consumers of the center.230 The 
Federal Drug-Free Communities (DFC) Support Program requires that community coalitions seeking 
grant funding from this program aimed at reducing youth substance abuse demonstrate representation 
from a dozen different sectors of the community (see figure below).231 The Comprehensive Addiction 
Recovery Act of 2016 also aligned many of its funding priorities behind what one interviewee called a 
"nothing about us without us" philosophy of substantively including community members in program 
and local policy development.232 
 
                                                          
227 Substance Abuse and Mental Health Services Administration, Risk and Protective Factors, available at 
https://www.samhsa.gov/capt/practicing-effective-prevention/prevention-behavioral-health/risk-protective-factors (last 
visited Mar. 25, 2018).  
228 COMPASSION FATIGUE (CHARLES R. FIGLEY, ED.) (1995). 
229 Patrick W. Corrigan et al., Challenging The Public Stigma of Mental Illness, 63 Psychiatric Services 963 (2012), available at 
https://ps.psychiatryonline.org/doi/pdf/10.1176/appi.ps.201100529.  
230 Brad Wright, Who Governs Federally Qualified Health Centers?, 38 J. Health Polit. Policy & Law 27 (2013), available at 
http://doi.org/10.1215/03616878-1898794.  
231 UNITED STATES GOVERNMENT ACCOUNTABILITY OFFICE, REPORT GAO-17-120, DRUG FREE COMMUNITIES SUPPORT PROGRAM (2017). 
232 E.g., Comprehensive Addiction Recovery Act of 2016, Public Law 114-198, secs. 302, 501. 
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Drug-Free Communities (DFC) Support Program: Required Coalition Members 
 
As stated by some of our interviewees, this form of engagement with the community of individuals and 
families directly affected by substance use disorder (as contrasted with “token” representation or “box 
checking” outreach) fosters trust within the at-risk community, which increases the likelihood of making 
stronger connections with treatment and recovery programs and services. Such engagement also 
increases the likelihood that proposed policies and programs will be responsive to the needs of the 
affected population. As stated by one interviewee from criminal justice, hearing from those directly 
affected by Substance Use Disorder is a “reality check” for those engaged in community program and 
policy response efforts, as many others around the table “haven't walked that walk or lived that 
lifestyle.” Another interviewee described examples of effective inclusion of those with lived experiences 
on community agencies, policymaking bodies and oversight boards, such as Local Coordinating Councils 
(LCCs). Currently, for LCCs, Indiana policy only requires the inclusion of community members if the 
council also is a grantee under the federal Drug Free Communities Support program (which funds 
community efforts to prevent or reduce youth substance abuse) or wish to apply for such grants.233 
C. Opportunities 
• Based upon feedback we heard from interviewees, education campaigns directed toward 
providers as well as the public on Medication Assisted Treatment and naloxone would be 
valuable. In July 2018, the Indiana Supreme Court, led by Chief Justice Loretta Rush, will offer an 
educational program on Medication Assisted Treatment to hundreds of representatives from 
                                                          
233 Indiana Local Coordinating Council Structure and Requirements Agreement, available at 
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the state’s local court systems, including judges, court staff, prosecutors, and public defenders. 
These efforts show promise of improving the knowledge, attitudes, beliefs, and evidence-
informed actions of key personnel within a critical response sector. Efforts should be 
undertaken to measure pre-intervention and post-intervention knowledge, attitudes, and 
beliefs to assess the program’s impact. 
• State and local policymaking bodies, community coalitions, initiatives, and programs related to 
Substance Use Disorder treatment, care, and response should, whenever possible, include the 
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CONCLUDING REMARKS 
This project has identified various law and policy interventions that can support the substance abuse 
response in Indiana. These interventions are not meant to be an exhaustive list of promising law and 
policy interventions. However, none of the data we examined, our interviewees, or our original research 
suggest that the opioid epidemic will be controlled, never-mind ended in a short time-frame. 
We recognize that, because there is no one solution to the epidemic, the federal government and the 
State of Indiana will continue to make incremental changes to laws and policies over the years ahead. 
Some of these changes no doubt will reduce the legal and policy barriers we and others have identified. 
Equally, some may have unintended consequences, creating new barriers. We believe that additional 
and continuing research is needed to further analyze the potential impact, implementation, and 
enforcement of these laws. Equally, the “laboratory of the states” no doubt will suggest intriguing new 
laws and policies that may or may not be a good “fit” for Indiana. There, too, continuing analysis will be 
required. We have identified several avenues for further research and analysis and look forward to 
continuing our work. 
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APPENDICES 
APPENDIX A: RESEARCH TEAM BIOGRAPHIES  
Nicolas P. Terry (Co-PI), Hall Render Professor of Law & Executive Director of the Hall Center for Health 
Law at Indiana University Robert H. McKinney School of Law. There, he teaches “Introduction to Health 
Care Law & Policy,” “Healthcare Quality & Safety,” and “Health Information Technology & Privacy.” 
Educated at Kingston University and the University of Cambridge, Professor Terry began his academic 
career as a member of the law faculty of the University of Exeter in England before joining the faculty at 
Saint Louis University School of Law. He has been a Senior Fellow at Melbourne Law School and held 
visiting faculty positions at various U.S. law schools. He is a well-known scholar on health law topics, 
nationally and internationally. His research interests lie primarily at the intersection of medicine, law, 
and information technology. His recent scholarship has dealt with health privacy, mobile health, the 
Internet of Things, social media, big data, and AI. He is broadly published in books, law review, medical 
and other journals. In addition to his scholarship, Professor Terry has been successful in leading in the 
conception, planning, and delivery of myriad interdisciplinary symposia at the IU McKinney School of 
Law. Terry has served on the Board of Advisors for the non-profit Patient Privacy Rights and was a 
member of the US Department of Health and Human Services Health IT Policy Committee’s Consumer 
Workgroup. In 2016, he testified before Congress on the regulation of mobile health apps. He is one of 
the permanent bloggers at Harvard Law School’s Bill of Health. His recent publications are at 
http://ssrn.com/author=183691, and you can find the Terry-Pasquale “The Week in Health Law” podcast 
at TWIHL.com. 
Ross D. Silverman (Co-PI), Professor of Health Policy and Management at the Indiana University Richard 
M. Fairbanks School of Public Health at IUPUI, and Professor of Public Health and Law at the Indiana 
University Robert H. McKinney School of Law. He is a member of the Indiana University Center for 
Health Policy and the Indiana University Center for Bioethics. Prior to 2013, Professor Silverman served 
15 years as faculty at Southern Illinois University Schools of Medicine and Law, including five years as 
chair of the medical school’s Department of Medical Humanities. His research addresses a wide array of 
subjects at the intersection of public and population health, healthcare, law, policy and policy 
surveillance, and ethics, with publications appearing in major journals in these fields, including the New 
England Journal of Medicine, JAMA, Health Affairs, Science, Annals of Surgery, and the Journal of Law, 
Medicine, and Ethics. He has had two recent publications in peer-reviewed journals related to Indiana 
opioid policy, law, and ethics, in Pain Medicine (doi: 10.1111/pme.12580) and JAMA (doi: 
10.1001/jama.2015.12672). He is an investigator conducting community-engaged research and law and 
policy analysis for the Indiana State Department of Health Prescription Drug Overdose Prevention for 
States contract with the Fairbanks School of Public Health (D. Watson, PI). Professor Silverman is the 
Associate Editor on Legal Epidemiology for the journal Public Health Reports, the official journal of the 
Office of the U.S. Surgeon General and the U.S. Public Health Service. 
Aila Hoss, Visiting Assistant Professor and IU Grand Challenge Fellow at Indiana University Robert H. 
McKinney School of Law. Her research explores topics in public health law, health policy development, 
and the impact of federal Indian law and Tribal law on health outcomes. Prior to joining the faculty at IU, 
Aila served as a staff attorney for the Centers for Disease Control and Prevention’s Public Health Law 
Program (PHLP), where she worked to improve public health through the development of legal tools and 
the provision of legal technical assistance to state, Tribal, local, and territorial governments. This 
included supporting the agency’s Ebola Emergency Operations Center and responding to legal research 
requests related to the Zika virus. Aila has published on a variety of health law topics in the Journal of 
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Law, Medicine and Ethics, the Journal of Public Health Management and Practice, and the CDC’s 
Morbidity and Mortality Weekly Report, among others, and has presented at national conferences 
including the Public Health Law Conference and the National Indian Health Board Public Health Summit. 
Aila serves as a faculty member for CDC University’s Working Effectively with Tribal Governments course 
and has previously served as a member of the Expert Review Workgroup for the CDC’s Legal 
Epidemiology Competency Model Project. 
Rebecca Critser, JD/MA candidate IU Robert H. McKinney School of Law, Indiana University Purdue 
University – Indianapolis. Her research explores the intersection of law and ethics and has published on 
topics related to end-of-life care. She currently serves as a law clerk with Indiana Legal Services, working 
on the LGBT and Medical Legal Partnership Projects. She previously worked for Cook Group in the area 
of quality assurance. She earned her BS in Animal Behavior from Bucknell University and will be sitting 
for the Indiana bar in July 2018.  
Emily Beukema, JD/MPH candidate Indiana University Robert H. McKinney School of Law, Indiana 
University Richard M. Fairbanks School of Public Health. Her research interests lie in health law and 
policy, specifically, access and affordability of care. She earned her Bachelor of Science in Biomedical 
Sciences from Western Michigan University and was first introduced to health law while working in a 
clinical setting as a medical scribe. 
Catherine Sterling, MPH candidate IU Richard M. Fairbanks School of Public Health, Indiana University 
Purdue University – Indianapolis. Her research interests include peoples with co-occurring SMI/SUD, as 
well as individuals experiencing homelessness. She currently is a Grant Specialist with the Health and 
Hospital Corporation of Marion County and oversees awards received by Eskenazi Health Midtown 
Community Mental Health and Indianapolis Emergency Medical Services. Her grant experience lies in 
federally funded awards, post-award coordination, and writing. She earned her Master’s in Public Affairs 
with a concentration in nonprofit management and a BA in English with a concentration in public and 
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APPENDIX B: DISCLOSURE TO INTERVIEWEES 
Interviewees were provided with a “Study Information Sheet” that provided details about the study and 
the limited degree of confidentiality that could be guaranteed.  
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APPENDIX C: SAMPLE QUESTIONS 
General Questions 
1. How would you describe the scope of the substance use problem (in Indiana, elsewhere, and/or 
generally)? 
1. How does your professional role(s) intersect with these concerns? 
2. To [you or your constituents] what would success look like regarding the opioid crisis [e.g., end 
of use of illegal drugs or treatment for users, or…] 
3. For you, what would constitute a successful law or policy intervention in the Substance Use 
Crisis? 
1. By what metric or measure would you assess the success or failure of the intervention? 
4. Can you identify legal or policy initiatives that have been successful in addressing the substance 
use problem? 
1. Are these successes national, regional, or local? 
2. Can you identify the evidence base(s) for these successful interventions? 
3. What do you believe contributed to the success of these initiatives? 
4. Do you believe such success(es) can be replicated elsewhere and, specifically, in 
Indiana? 
1. If so, how? 
2. If not, why not? 
5. Can you identify legal or policy initiatives (or the implementation/interpretation of 
laws/policies) that have inhibited evidence-based responses or interventions in Indiana/for 
Indiana residents? 
1. Are these barriers federal, state, regional, or local laws or policies? 
2. Can you identify the evidence base(s) for the conclusion that these legal or policy 
initiatives have created barriers to successful interventions? 
3. What recommendations/examples do you have for how to successfully overcome such 
barriers? 
 
Domain-Specific Questions (Examples) 
1. Significant work coming out of state courts initiatives and some new funding are concentrating 
on Medication-Assisted Treatment (MAT). From your perspective can you evaluate the level of 
available treatments in your [] 
2. Would you like to make any other comments on MAT or more broadly on harm-reduction 
naloxone, etc. 
…… 
1. Please unpack the [prisoner] “re-entry” issue for us (e.g., housing, healthcare, jobs, food, 
stigma…). 
2. How would you rank these as far as level of risk for those facing re-entry, particularly if they 
have a history of addictions? 
3. We know that the individuals being released from the criminal justice system are particularly 
vulnerable. Can you speak to the continuity of care between the criminal justice system and 
legal reentry? Can you speak to persons being released from DoC and how they are reconnected 
to services such as Medicaid? 
Legal and Policy Best Practices in Response to the Substance Abuse Crisis 
64  |  April 26, 2018 
 
…… 
1. Turning to legal and regulatory issues…. What are the real or perceived legal barriers to improve 
data sharing of opioid-related data? 
2. Specifically, can you speak to the relationship between the HIPAA privacy rule and 42 CFR Part 2. 
Way forward? 
